

METHOD FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS
FROM 2,2-DISUBSTITUTED EPOXIDES

5

TECHNICAL FIELD

THIS INVENTION relates to biocatalytic reactions, and more particularly to the use of
10 enantiomer selective hydrolases to obtain optically active epoxides and vicinal diols.

BACKGROUND

Optically active epoxides and vicinal diols are versatile fine chemical intermediates for use
15 in the production of pharmaceuticals, agrochemicals, ferro-electric liquid crystals and
flavours and fragrances. Epoxides are highly reactive electrophiles because of the strain
inherent in the three-membered ring and the electronegativity of the oxygen. Epoxides react
readily with various O-, N-, S-, and C-nucleophiles, acids, bases, reducing and oxidizing
agents, allowing the production to bifunctional molecules. Vicinal diols, employed as their
20 highly reactive cyclic sulfites and sulfates, act like epoxide-like synthons with a broad range
of nucleophiles. The possibility of double nucleophilic displacement reactions with amidines
and azide, allow access to dihydroimidazole derivatives, aziridines, diamines and diazides.
Since enantiopure epoxides and vicinal diols can stereospecifically be interconverted, they
can be regarded as synthetic equivalents.

25

Optically active 2,2-disubstituted epoxides (TDE) and 2-substituted-1,2-diols (DVD) have
considerable synthetic potential, since these compounds constitute highly flexible molecular
scaffolds which can be converted to valuable optically active tertiary alcohols, α -
methylamino acids and α -hydroxy- α -methyl carboxylic acids (Steinreiber *et al.* 2000).

30

Epoxide hydrolases (EC 3.3.2.3) are hydrolytic enzymes that convert epoxides to vicinal
diols by ring-opening of the epoxide with water. Epoxide hydrolases are present in
mammals, plants, insects and microorganisms.

35

SUMMARY

The invention is based in part on the surprising discovery by the inventors that certain microorganisms express epoxide hydrolases with high enantioselectivity. The microorganisms of the invention selectively hydrolyse 2,2-disubstituted epoxides or selectively form 2-substituted-1,2-diols and their genomes encode polypeptides having highly enantioselective epoxide hydrolase activity.

More specifically, the invention provides a process for obtaining an optically active epoxide and/ or an optically active vicinal diol, which process includes the steps of: providing an enantiomeric mixture of a 2,2-disubstituted epoxide (TDE); creating a reaction mixture by adding to the enantiomeric mixture a polypeptide, or a functional fragment thereof, having enantioselective 2,2-disubstituted epoxide hydrolase activity, the polypeptide being a polypeptide encoded by a gene of a yeast cell; incubating the reaction mixture; and recovering from the reaction mixture: (a) an enantiopure, or a substantially enantiopure, 2,2-disubstituted vicinal diol (DVD); (b) an enantiopure, or a substantially enantiopure, 2,2-disubstituted epoxide; or (c) an enantiopure, or a substantially enantiopure, 2,2-disubstituted vicinal diol and an enantiopure, or a substantially enantiopure, 2,2-disubstituted epoxide.



Another aspect of the invention is a process for obtaining an optically active epoxide and/or an optically active vicinal diol, which process includes the steps of: providing an enantiomeric mixture of a 2,2-disubstituted epoxide; creating a reaction mixture by adding to the enantiomeric mixture a cell comprising a nucleic acid encoding, and capable of expressing, a polypeptide having enantioselective 2,2-disubstituted epoxide hydrolase activity, the polypeptide being a polypeptide encoded by a gene of a yeast cell; incubating the reaction mixture; and recovering from the reaction mixture: (a) an enantiopure, or a substantially enantiopure, 2,2-disubstituted vicinal diol; (b) an enantiopure, or a substantially enantiopure, 2,2-disubstituted epoxide; or (c) an enantiopure, or a substantially enantiopure, 2,2-disubstituted vicinal diol and an enantiopure, or a substantially enantiopure, 2,2-disubstituted epoxide.

The following embodiments apply to both of the above processes. The cell can be a yeast cell. The polypeptide can be encoded by an endogenous gene of the cell or the cell can be a recombinant cell, the polypeptide being encoded by a nucleic acid sequence with which

the cell is transformed. The nucleic acid sequence can be an exogenous nucleic acid sequence, a heterologous nucleic acid sequence, or a homologous nucleic acid sequence. The polypeptide can be a full-length yeast epoxide hydrolase or a functional fragment of a full length yeast epoxide hydrolase.

Moreover both processes can be carried out at a pH from 5 to 10. They can be carried out at a temperature of 0°C to 70 °C. In the processes, the concentration of the 2,2-disubstituted epoxide can be at least equal to the solubility of the 2,2-disubstituted epoxide in water.

In both processes, the 2,2-disubstituted epoxide of the enantiomeric mixture can be a compound of the general formula (I) and the vicinal diol produced by the process is a compound of the general formula (II),



wherein:

R₁ and R₂ are, independently of each other, selected from the group consisting of a variably substituted straight-chain or branched alkyl group, a variably substituted straight-chain or branched alkenyl group, a variably substituted straight-chain or branched alkynyl group, a variably substituted cycloalkyl group as well as cycloalkenyl groups, a variably substituted aryl group, a variably substituted aryl alkyl group, a variably substituted heterocyclic group, a variably substituted straight-chain or branched alkoxy group, a variably substituted straight-chain or branched alkenyloxy group, a variably substituted aryloxy group, a variably substituted aryl alkyloxy group, a variably substituted alkylthio group, a variably substituted alkoxy carbonyl group, a variably substituted straight chain or branched alkylamino or alkenyl amino group, a variably substituted arylamino or arylalkylamino group, a variably substituted carbamoyl group, a variably substituted acyl group, and a functional group; or wherein R₁ and R₂, together as a whole unit are a carbocycle with 5-7 atoms or a heterocycle with 5 to 7 carbon atoms.

Moreover, in the processes, the enantiomeric mixture can be a racemic mixture or a mixture of any ratio of amounts of the enantiomers. The processes can include adding to the reaction mixture water and at least one water-immiscible solvent, including, for example, toluene, 1,1,2-trichlorotrifluoroethane, methyl *tert*-butyl ether, methyl isobutyl ketone, 5 dibutyl-*o*-phthalate, aliphatic alcohols containing 6 to 9 carbon atoms or aliphatic hydrocarbons containing 6 to 16 carbon atoms. Alternatively, or in addition, the processes can include adding to the reaction mixture water and at least one water-miscible organic solvent, for example, acetone, methanol, ethanol, propanol, isopropanol, acetonitrile, dimethylsulfoxide, *N,N*-dimethylformamide, or *N*-methylpyrrolidine. In addition, or 10 alternatively, one or more surfactants, one or more cyclodextrins, or one or more phase-transfer catalysts can be added to the reaction mixtures. Both processes can include stopping the reaction when one enantiomer of the epoxide and/or vicinal diol is in excess compared to the other enantiomer of the epoxide and/or vicinal diol. Furthermore, the processes can include recovering continuously during the reaction the optically active 15 epoxide and/or the optically active vicinal diol produced by the reaction directly from the reaction mixture.

In both processes the yeast cell can be of one of the following exemplary genera: *Arxula*, *Brettanomyces*, *Bullera*, *Bulleromyces*, *Candida*, *Cryptococcus*, *Debaryomyces*, *Dekkera*, 20 *Exophiala*, *Geotrichum*, *Hormonema*, *Issatchenkia*, *Kluyveromyces*, *Lipomyces*, *Mastigomyces*, *Myxozyma*, *Pichia*, *Rhodospiridium*, *Rhodotorula*, *Sporidiobolus*, *Sporobolomyces*, *Trichosporon*, *Wingea*, or *Yarrowia*.

Moreover, in the processes, the yeast cell can be of one of the following exemplary species: 25 *Arxula adenivorans*, *Arxula terrestris*, *Brettanomyces bruxellensis*, *Brettanomyces naardenensis*, *Brettanomyces anomalus*, *Brettanomyces species* (e.g. NCYC 3151), *Bullera dendrophila*, *Bulleromyces albus*, *Candida albicans*, *Candida fabianii*, *Candida glabrata*, *Candida haemulonii*, *Candida intermedia*, *Candida magnoliae*, *Candida parapsilosis*, *Candida rugosa*, *Candida tenuis*, *Candida tropicalis*, *Candida famata*, *Candida kruisei*, 30 *Candida sp. (new) rel to C. sorbophila*, *Cryptococcus albidus*, *Cryptococcus amylolentus*, *Cryptococcus bhutanensis*, *Cryptococcus curvatus*, *Cryptococcus gastricus*, *Cryptococcus humicola*, *Cryptococcus hungaricus*, *Cryptococcus laurentii*, *Cryptococcus luteolus*, *Cryptococcus macerans*, *Cryptococcus podzolicus*, *Cryptococcus terreus*, *Cryptococcus macerans*, *Debaryomyces hansenii*, *Dekkera anomala*, *Exophiala dermatitidis*, *Geotrichum species* (e.g. UOFS Y-0111), *Hormonema species* (e.g. NCYC 3171), *Issatchenkia* 35

occidentalis, *Kluyveromyces marxianus*, *Lipomyces species* (e.g. UOFS Y-2159), *Lipomyces tetrasporus*, *Mastigomyces philipporii*, *Myxozyma melibiosii*, *Pichia anomala*, *Pichia finlandica*, *Pichia guillermondii*, *Pichia haplophila*, *Rhodosporidium lusitaniae*, *Rhodosporidium paludigenum*, *Rhodosporidium sphaerocarpum*, *Rhodosporidium*
 5 *toruloides*, *Rhodosporidium paludigenum*, *Rhodotorula araucariae*, *Rhodotorula glutinis*, *Rhodotorula minuta*, *Rhodotorula minuta* var. *minuta*, *Rhodotorula mucilaginosa*, *Rhodotorula phillyla*, *Rhodotorula rubra*, *Rhodotorula species* (e.g. UOFS Y-2042), *Rhodotorula species* (e.g. UOFS Y-0448), *Rhodotorula species* (e.g. NCYC 3193), *Rhodotorula species* (e.g. UOFS Y-0139), *Rhodotorula species* (e.g. UOFS Y-0560),
 10 *Rhodotorula aurantiaca*, *Rhodotorula species* (e.g. NCYC 3224), *Rhodotorula sp. "mucilaginosa"*, *Sporidiobolus salmonicolor*, *Sporobolomyces holsaticus*, *Sporobolomyces roseus*, *Sporobolomyces tsugae*, *Trichosporon beigellii*, *Trichosporon cutaneum* var. *cutaneum*, *Trichosporon delbrueckii*, *Trichosporon jirovecii*, *Trichosporon mucoides*, *Trichosporon ovoides*, *Trichosporon pullulans*, *Trichosporon species* (e.g. UOFS Y-0861),
 15 *Trichosporon species* (e.g. UOFS Y-1615), *Trichosporon species* (e.g. UOFS Y-0451), *Trichosporon species* (e.g. NCYC 3212), *Trichosporon species* (e.g. UOFS Y-0449), *Trichosporon species* (e.g. NCYC 3211), *Trichosporon species* (e.g. UOFS Y-2113), *Trichosporon species* (e.g. NCYC 3210), *Trichosporon moniliiforme*, *Trichosporon montevideense*, *Wingea robertsiae*, or *Yarrowia lipolytica*.

20 The yeast cell can also be of any of the other genera, species, or strains disclosed herein.

Another aspect of the invention is a method for producing a polypeptide, which process includes the steps of: providing a cell comprising a nucleic acid encoding and capable of
 25 expressing a polypeptide that has enantioselective 2,2-disubstituted epoxide hydrolase activity; culturing the cell; and recovering the polypeptide from the culture. Recovering the polypeptide from the culture includes, for example, recovering it from the medium in which the cell was cultured or recovering it from the cell *per se*. The cell can be a yeast cell. The polypeptide can be encoded by an endogenous gene of the cell or the cell can be a
 30 recombinant cell, the polypeptide being encoded by a nucleic acid sequence with which the cell is transformed. The nucleic acid sequence can be an exogenous nucleic acid sequence, a heterologous nucleic acid sequence, or a homologous nucleic acid sequence. The polypeptide can be a full-length yeast epoxide hydrolase or a functional fragment of a full-length yeast epoxide hydrolase. The cell can be of any of the yeast genera, species, or
 35 strains disclosed herein or any recombinant cell disclosed herein.

The invention also features a crude or pure enzyme preparation which includes an isolated polypeptide having enantioselective 2,2-disubstituted epoxide hydrolase activity. The polypeptide can be one encoded by any of the yeast genera, species, or strains disclosed herein or one encoded by a recombinant cell.

5

In another aspect, the invention features a substantially pure culture of cells, a substantial number of which comprise a nucleic acid encoding, and are capable of expressing, a polypeptide having enantioselective 2,2-disubstituted epoxide hydrolase activity. The cells can be recombinant cells or cells of any of the yeast genera, species, or strains disclosed herein.

10

Another embodiment of the invention is an isolated cell, the cell comprising a nucleic acid encoding a polypeptide having enantioselective 2,2-disubstituted epoxide hydrolase activity, the cell being capable of expressing the polypeptide. The cell can be any of those disclosed herein.

15

The invention also features an isolated DNA that includes: (a) a nucleic acid sequence that encodes a polypeptide that has enantioselective 2,2 disubstituted epoxide hydrolase activity and that hybridizes under highly stringent conditions to the complement of a sequence that can be SEQ ID NO: 8, 9, 10, 11, 12, 13, or 14; or (b) the complement of the nucleic acid sequence. The nucleic acid sequence can encode a polypeptide that includes an amino acid sequence that can be SEQ ID NO: 1, 2, 3, 4, 5, 6, or 7. The nucleic acid sequence can be, for example, one of those with SEQ ID NOs: 8, 9, 10, 11, 12, 13, or 14.

20

Also provided by the invention is an isolated DNA that includes: (a) a nucleic acid sequence that is at least 55% identical to a sequence that can be SEQ ID NO: 8, 9, 10, 11, 12, 13, or 14; or (b) the complement of the nucleic acid sequence, the nucleic acid sequence encoding a polypeptide that has enantioselective 2,2-disubstituted epoxide hydrolase activity.

25

30

Another aspect of the invention is an isolated DNA that includes: (a) a nucleic acid sequence that encodes a polypeptide consisting of an amino acid sequence that is at least 55% identical to a sequence that can be SEQ ID NOs: 1, 2, 3, 4, 5, 6, or 7; or (b) the complement of the nucleic acid sequence, the polypeptide having enantioselective 2,2-disubstituted epoxide hydrolase activity.

35

Also included are vectors (e.g., those in which the coding sequence is operably linked to a transcriptional regulatory element) containing any of the above DNAs and cells (e.g., eukaryotic or prokaryotic cells) containing such vectors.

- 5 Also provided by the invention is an isolated polypeptide encoded by any of the above DNAs. The polypeptide can include an amino acid sequence that is at least 55% identical to SEQ ID NOs: 1, 2, 3, 4, 5, 6 or 7, the polypeptide having enantioselective 2,2-disubstituted epoxide hydrolase activity. The polypeptide can also include: (a) a sequence that can be SEQ ID NO: 1, 2, 3, 4, 5, 6, or 7, or a functional fragment of the sequence; or
10 (b) the sequence of (a), but with no more than five conservative substitutions, the polypeptide having enantioselective 2,2-disubstituted epoxide hydrolase activity.

In another embodiment the invention features an isolated antibody (e.g., a polyclonal or a monoclonal antibody) that binds to any of the above-described polypeptides.

15

The term "exogenous" as used herein with reference to nucleic acid and a particular host cell refers to any nucleic acid that does not occur in (and cannot be obtained from) that particular cell as found in nature. Thus, a non-naturally-occurring nucleic acid is considered to be exogenous to a host cell once introduced into the host cell. It is important to note that
20 non-naturally-occurring nucleic acids can contain nucleic acid subsequences or fragments of nucleic acid sequences that are found in nature provided the nucleic acid as a whole does not exist in nature. For example, a nucleic acid molecule containing a genomic DNA sequence within an expression vector is non-naturally-occurring nucleic acid, and thus is exogenous to a host cell once introduced into the host cell, since that nucleic acid molecule as a whole (genomic DNA plus vector DNA) does not exist in nature. Thus, any vector,
25 autonomously replicating plasmid, or virus (e.g., retrovirus, adenovirus, or herpes virus) that as a whole does not exist in nature is considered to be non-naturally-occurring nucleic acid. It follows that genomic DNA fragments produced by PCR or restriction endonuclease treatment as well as cDNAs are considered to be non-naturally-occurring nucleic acid since
30 they exist as separate molecules not found in nature. It also follows that any nucleic acid containing a promoter sequence and polypeptide-encoding sequence (e.g., cDNA or genomic DNA) in an arrangement not found in nature is non-naturally-occurring nucleic acid. Nucleic acid that is naturally-occurring can be exogenous to a particular cell. For example, an entire chromosome isolated from a cell of yeast x is an exogenous nucleic acid
35 with respect to a cell of yeast y once that chromosome is introduced into a cell of yeast y.

It will be clear from the above that "exogenous" nucleic acids can be "homologous" or "heterologous" nucleic acids. As used herein, "homologous" nucleic acids are those that are derived from a cell of the same species as the host cell and "heterologous" nucleic acids are those that are derived from a species other than that of the host cell.

5

In contrast, the term "endogenous" as used herein with reference to nucleic acids or genes and a particular cell refers to any nucleic acid or gene that does occur in (and can be obtained from) that particular cell as found in nature.

10 **The alkyl group** can be a straight chain or branched alkyl group with 1 to 12 carbon atoms. The alkyl group can be selected from the group consisting of: methyl-; ethyl-; propyl-; isopropyl-; butyl-; isobutyl-; s-butyl-; t-butyl-; pent-1-yl-; pent-2-yl-; pent-3-yl-; 2-methylbut-1-yl-; 3-methylbut-1-yl-; 2-methylbut-2-yl-; 3-methylbut-2-yl-; hex-1-yl-; hex-2-yl-; hex-3-yl-; 1-methylpent-1-yl-; 2-methylpent-1-yl-; 3-methylpent-1-yl-; 2-methylpent-2-yl-; 3-methylpent-2-yl-; 4-methylpent-2-yl-; 2-methylpent-3-yl-; 3-methylpent-3-yl-; 2-ethylbut-1-yl-; hept-1-yl-; hept-2-yl-; hept-3-yl-; hept-4-yl-; 1-methylhex-1-yl-; 2-methylhex-1-yl-; 3-methylhex-1-yl-; 4-methylhex-1-yl-; 5-methylhex-1-yl-; 2-methylhex-2-yl-; 3-methylhex-2-yl-; 4-methylhex-2-yl-; 5-methylhex-2-yl-; 2-methylhex-3-yl-; 3-methylhex-3-yl-; 4-methylhex-3-yl-; 5-methylhex-3-yl-; 2-methylhex-4-yl-; 1,1-dimethylpent-1-yl-; 1,2-dimethylpent-1-yl-; 1,3-dimethylpent-1-yl-; 1,4-dimethylpent-1-yl-; 2,2-dimethylpent-1-yl-; 2,3-dimethylpent-1-yl-; 2,4-dimethylpent-1-yl-; 2,5-dimethylpent-1-yl-; 3,3-dimethylpent-1-yl-; 3,4-dimethylpent-1-yl-; 3,5-dimethylpent-1-yl-; 4,4-dimethylpent-1-yl-; 4,5-dimethylpent-1-yl-; 5,5-dimethylpent-1-yl-; 2,2-dimethylpent-2-yl-; 2,3-dimethylpent-2-yl-; 2,4-dimethylpent-2-yl-; 3,3-dimethylpent-2-yl-; 3,4-dimethylpent-2-yl-; 2,2-dimethylpent-3-yl-; 2,3-dimethylpent-3-yl-; 2,4-dimethylpent-3-yl-; 2,2-dimethylpent-4-yl-; 2-ethylpent-1-yl-; 3-ethylpent-1-yl-; 1,1,2-trimethylbut-1-yl-; 1,2,2-trimethylbut-1-yl-; 1,2,3-trimethylbut-1-yl-; 2,2,3-trimethylbut-1-yl-; 2,3,3-trimethylbut-1-yl-; 2,3,3-but-2-yl-; 2-isopropylbut-1-yl-; 2-isopropylbut-2-yl-; oct-1-yl-; oct-2-yl-; oct-3-yl-; oct-4-yl-; 2-methylhept-1-yl-; 3-methylhept-1-yl-; 4-methylhept-1-yl-; 5-methylhept-1-yl-; 6-methylhept-1-yl-; 2-methylhept-2-yl-; 3-methylhept-2-yl-; 4-methylhept-2-yl-; 5-methylhept-2-yl-; 6-methylhept-2-yl-; 2-methylhept-3-yl-; 3-methylhept-3-yl-; 4-methylhept-3-yl-; 5-methylhept-3-yl-; 6-methylhept-3-yl-; 2-methylhept-4-yl-; 3-methylhept-4-yl-; 4-methylhept-4-yl-; 2,2-dimethylhex-1-yl-; 2,3-dimethylhex-1-yl-; 2,4-dimethylhex-1-yl-; 2,5-dimethylhex-1-yl-; 3,3-dimethylhex-1-yl-; 3,4-dimethylhex-1-yl-; 3,5-dimethylhex-1-yl-; 4,4-dimethylhex-1-yl-; 4,5-dimethylhex-1-yl-; 5,5-dimethylhex-1-yl-; 2,3-dimethylhex-2-yl-; 2,4-dimethylhex-2-yl-; 2,5-dimethylhex-2-yl-; 3,3-dimethylhex-2-yl-; 3,4-dimethylhex-2-yl-; 3,5-dimethylhex-2-yl-; 4,4-

dimethylhex-2-yl-; 4,5-dimethylhex-2-yl-; 5,5-dimethylhex-2-yl-; 2,2-dimethylhex-3-yl-; 2,3-dimethylhex-3-yl-; 2,4-dimethylhex-3-yl-; 2,5-dimethylhex-3-yl-; 3,3-dimethylhex-3-yl-; 3,4-dimethylhex-3-yl-; 3,5-dimethylhex-3-yl-; 4,4-dimethylhex-3-yl-; 4,5-dimethylhex-3-yl-; 5,5-dimethylhex-3-yl-; 2,2,3-trimethylpent-1-yl-; 2,2,4-trimethylpent-1-yl-; 2,3,3-trimethylpent-1-yl-; 2,3,4-trimethylpent-1-yl-; 3,3,4-trimethylpent-1-yl-; 3,4,4-trimethylpent-1-yl-; 2,4,4-trimethylpent-1-yl-; 2,3,3-trimethylpent-2-yl-; 2,3,4-trimethylpent-2-yl-; 3,3,4-trimethylpent-2-yl-; 3,4,4-trimethylpent-2-yl-; 2,4,4-trimethylpent-2-yl-; 2,2,3-trimethylpent-3-yl-; 2-methyl-3-ethylpent-1-yl-; 3-ethyl-3-methylpent-1-yl-; 3-ethyl-4-methylpent-1-yl-; (3-methylhex-3-yl)methyl-; (4-methylhex-3-yl)methyl-; (5-methylhex-3-yl)methyl-; (2-methylhex-2-yl)methyl-; 2-methyl-3-ethylpent-2-yl-; 3-ethyl-3-methylpent-2-yl-; 3-ethyl-4-methylpent-2-yl-; 2-methyl-2-ethylpent-3-yl-; 2-methyl-3-ethylpent-3-yl-; 2,2,3,3-tetramethylbut-1-yl-; 2-ethyl-3,3-dimethylbut-2-yl-; 2-isopropyl-3-methylbut-2-yl-; (3-ethylpent-3-yl)methyl-; (2,3-dimethylpent-3-yl)methyl-; (2,4-dimethylpent-3-yl)methyl-; non-1-yl-; non-2-yl-; non-3-yl-; non-4-yl-; non-5-yl-; 2-methyloct-1-yl-; 3-methyloct-1-yl-; 4-methyloct-1-yl-; 5-methyloct-1-yl-; 6-methyloct-1-yl-; 7-methyloct-1-yl-; 2-methyloct-2-yl-; 3-methyloct-2-yl-; 4-methyloct-2-yl-; 5-methyloct-2-yl-; 6-methyloct-2-yl-; 7-methyloct-2-yl-; 2-methyloct-3-yl-; 3-methyloct-3-yl-; 4-methyloct-3-yl-; 5-methyloct-3-yl-; 6-methyloct-3-yl-; 7-methyloct-3-yl-; 2-methyloct-4-yl-; 3-methyloct-4-yl-; 4-methyloct-4-yl-; 5-methyloct-4-yl-; 6-methyloct-4-yl-; 7-methyloct-4-yl-; 2,2-dimethylhept-1-yl-; 2,3-dimethylhept-1-yl-; 2,4-dimethylhept-1-yl-; 2,5-dimethylhept-1-yl-; 2,6-dimethylhept-1-yl-; 3,3-dimethylhept-1-yl-; 3,4-dimethylhept-1-yl-; 3,5-dimethylhept-1-yl-; 3,6-dimethylhept-1-yl-; 4,4-dimethylhept-1-yl-; 4,5-dimethylhept-1-yl-; 4,6-dimethylhept-1-yl-; 5,5-dimethylhept-1-yl-; 5,6-dimethylhept-1-yl-; 6,6-dimethylhept-1-yl-; 2,3-dimethylhept-2-yl-; 2,4-dimethylhept-2-yl-; 2,5-dimethylhept-2-yl-; 2,6-dimethylhept-2-yl-; 3,3-dimethylhept-2-yl-; 3,4-dimethylhept-2-yl-; 3,5-dimethylhept-2-yl-; 3,6-dimethylhept-2-yl-; 4,4-dimethylhept-2-yl-; 4,5-dimethylhept-2-yl-; 4,6-dimethylhept-2-yl-; 5,5-dimethylhept-2-yl-; 5,6-dimethylhept-2-yl-; 6,6-dimethylhept-2-yl-; 2,2-dimethylhept-3-yl-; 2,3-dimethylhept-3-yl-; 2,4-dimethylhept-3-yl-; 2,5-dimethylhept-3-yl-; 2,6-dimethylhept-3-yl-; 3,4-dimethylhept-3-yl-; 3,5-dimethylhept-3-yl-; 3,6-dimethylhept-3-yl-; 4,4-dimethylhept-3-yl-; 4,5-dimethylhept-3-yl-; 4,6-dimethylhept-3-yl-; 5,5-dimethylhept-3-yl-; 5,6-dimethylhept-3-yl-; 6,6-dimethylhept-3-yl-; 3-ethylhept-1-yl-; 3-ethylhept-1-yl-; 4-ethylhept-1-yl-; 3-ethylhept-2-yl-; 4-ethylhept-2-yl-; 5-ethylhept-2-yl-; 3-ethylhept-3-yl-; 4-ethylhept-3-yl-; 5-ethylhept-3-yl-; 3-ethylhept-4-yl-; 4-ethylhept-4-yl-; 2,2,3-trimethylhex-1-yl-; 2,2,4-trimethylhex-1-yl-; 2,2,5-trimethylhex-1-yl-; 2,3,3-trimethylhex-1-yl-; 2,3,4-trimethylhex-1-yl-; 2,3,5-trimethylhex-1-yl-; 2,4,4-trimethylhex-1-yl-; 2,4,5-trimethylhex-1-yl-; 2,5,5-trimethylhex-1-yl-; 3,3,4-trimethylhex-1-yl-; 3,3,5-trimethylhex-1-yl-; 4,4,5-trimethylhex-1-yl-; 4,5,5-trimethylhex-1-yl-; 2,3,3-trimethylhex-2-yl-; 2,3,4-trimethylhex-2-yl-;

2,3,5-trimethylhex-2-yl-; 2,4,4-trimethylhex-2-yl-; 2,4,5-trimethylhex-2-yl-; 2,5,5-trimethylhex-2-yl-; 3,3,4-trimethylhex-2-yl-; 3,3,5-trimethylhex-2-yl-; 3,4,4-trimethylhex-2-yl-; 3,4,5-trimethylhex-2-yl-; 3,5,5-trimethylhex-2-yl-; 4,4,5-trimethylhex-2-yl-; 4,5,5-trimethylhex-2-yl-; 2,2,3-trimethylhex-3-yl-; 2,2,4-trimethylhex-3-yl-; 2,2,5-trimethylhex-3-yl-; 2,3,4-trimethylhex-3-yl-; 2,3,5-trimethylhex-3-yl-; 2,4,4-trimethylhex-3-yl-; 2,4,5-trimethylhex-3-yl-; 2,5,5-trimethylhex-3-yl-; 4,4,5-trimethylhex-3-yl-; 4,5,5-trimethylhex-3-yl-; (2-methylhex-3-yl)methyl-; 3-ethyl-2-methylhex-1-yl-; 3-ethyl-3-methylhex-1-yl-; 3-ethyl-4-methylhex-1-yl-; 3-ethyl-5-methylhex-1-yl-; 4-ethyl-2-methylhex-1-yl-; 4-ethyl-3-methylhex-1-yl-; 4-ethyl-4-methylhex-1-yl-; 4-ethyl-5-methylhex-1-yl-; (2-methylhex-1-yl)methyl-; (3-methylhex-1-yl)methyl-; (4-methylhex-1-yl)methyl-; (5-methylhex-1-yl)methyl-; (6-methylhex-1-yl)methyl-; 3-isopropylhex-1-yl-; 4-ethyl-5-methylhex-1-yl-; 3-ethyl-3-methylhex-2-yl-; 3-ethyl-4-methylhex-2-yl-; 3-ethyl-5-methylhex-2-yl-; 4-ethyl-2-methylhex-2-yl-; 4-ethyl-3-methylhex-2-yl-; 4-ethyl-4-methylhex-2-yl-; 4-ethyl-5-methylhex-2-yl-; 3-isopropylhex-2-yl-; 4-ethyl-5-methylhex-2-yl-; 3-ethyl-2-methylhex-3-yl-; 3-ethyl-4-methylhex-3-yl-; 3-ethyl-5-methylhex-3-yl-; 4-ethyl-2-methylhex-3-yl-; 4-ethyl-3-methylhex-3-yl-; 4-ethyl-4-methylhex-3-yl-; 4-ethyl-5-methylhex-3-yl-; 4-isopropylhex-1-yl-; 2,2,3,3-tetramethylpent-1-yl-; 2,2,3,4-tetramethylpent-1-yl-; 2,2,4,4-tetramethylpent-1-yl-; 2,3,3,4-tetramethylpent-1-yl-; 2,3,4,4-tetramethylpent-1-yl-; 2,3,4,4-tetramethylpent-1-yl-; 3,3,4,4-tetramethylpent-1-yl-; 2,3,3,4-tetramethylpent-2-yl-; 2,3,4,4-tetramethylpent-2-yl-; 2,3,4,4-tetramethylpent-2-yl-; 3,3,4,4-tetramethylpent-2-yl-; 2,2,3,4-tetramethylpent-3-yl-; 2,2,4,4-tetramethylpent-3-yl-; 2,3,4,4-tetramethylpent-3-yl-; 2,3,4,4-tetramethylpent-3-yl-; (3-ethylhex-3-yl)methyl-; (4-ethylhex-3-yl)methyl-; (5-methylhept-3-yl)methyl-; 2,4-dimethyl-3-ethylpent-1-yl-; 3,4-dimethyl-3-ethylpent-1-yl-; 4,4-dimethyl-3-ethylpent-1-yl-; 2-ethyl-2-methylhex-1-yl-; 3-ethyl-2-methylhex-1-yl-; 4-ethyl-2-methylhex-1-yl-; 2-ethyl-3-methylhex-1-yl-; 2-ethyl-4-methylhex-1-yl-; 3-ethyl-3-methylhex-1-yl-; 3-ethyl-4-methylhex-1-yl-; 3-ethyl-5-methylhex-1-yl-; 4-ethyl-3-methylhex-1-yl-; 4-ethyl-4-methylhex-1-yl-; 4-ethyl-5-methylhex-1-yl-; and the like from dec-1-yl-; dec-2-yl-; dec-3-yl-; dec-4-yl-; dec-5-yl-; dec-6-yl-; undec-1-yl-; undec-2-yl-; undec-3-yl-; undec-4-yl-; undec-5-yl-; undec-6-yl-; undec-7-yl-; dodec-1-yl-; dodec-2-yl-; dodec-3-yl-; dodec-4-yl-; dodec-5-yl-; dodec-6-yl groups. Preferably, the alkyl group is a straight chain or branched alkyl group with 1 to 8 carbon atoms.

The alkenyl group can be a straight chain or branched alkenyl group having 2-12 carbon atoms. The alkenyl group can be selected from the group consisting of: vinyl-; allyl-; α -methallyl-; β -methallyl-; 1-propenyl-; isopropenyl-; 1-butenyl-; 2-butenyl-; 3-butenyl-; 1-buten-2-yl-; 1-buten-3-yl-; 1-methyl-1-propenyl-; 2-methyl-1-propenyl-; 1-pentenyl-; 2-pentenyl-; 3-

pentenyl-; 4-pentenyl-; 1-penten-2-yl-; 1-penten-3-yl-; 2-methyl-1-butenyl-; 1-hexenyl-; 2-hexenyl-; 3-hexenyl-; 4-hexenyl-; 5-hexenyl-; 1-heptenyl-; 2-heptenyl-; 3-heptenyl-; 4-heptenyl-; 5-heptenyl-; 6-heptenyl-; 1-octenyl-; 2-octenyl-; 3-octenyl-; 4-octenyl-; 5-octenyl-; 6-octenyl-; 7-octenyl-; 1-nonenyl-; 2-nonenyl-; 3-nonenyl-; 4-nonenyl-; 5-nonenyl-; 6-nonenyl-; 7-nonenyl-; 8-nonenyl-; 1-decenyl-; 2-decenyl-; 3-decenyl-; 4-decenyl-; 5-decenyl-; 6-decenyl-; 7-decenyl-; 8-decenyl-; 9-decenyl-; 1-undecenyl-; 2-undecenyl-; 3-undecenyl-; 4-undecenyl-; 5-undecenyl-; 6-undecenyl-; 7-undecenyl-; 8-undecenyl-; 9-undecenyl-; 10-undecenyl-; 1-dodecenyl-; 2-dodecenyl-; 3-dodecenyl-; 4-dodecenyl-; 5-dodecenyl-; 6-dodecenyl-; 7-dodecenyl-; 8-dodecenyl-; 9-dodecenyl-; 10-dodecenyl-; 11-dodecenyl groups; and related branched isomers. Preferably, the group is a straight chain or branched alkenyl group with 2 to 8 carbon atoms.

The alkynyl group can be a straight chain or branched alkynyl group having 2-12 carbon atoms. The alkynyl group can be selected from the group consisting of: ethynyl-; 1-propynyl-; 2-propynyl-; 1-butylnyl-; 2-butylnyl-; 3-butylnyl-; 1-pentylnyl-; 2-pentylnyl-; 3-pentylnyl-; 4-pentylnyl-; 1-hexynyl-; 2-hexynyl-; 3-hexynyl-; 4-hexynyl-; 5-hexynyl-; 1-heptylnyl-; 2-heptylnyl-; 3-heptylnyl-; 4-heptylnyl-; 5-heptylnyl-; 6-heptylnyl-; 1-octynyl-; 2-octynyl-; 3-octynyl-; 4-octynyl-; 5-octynyl-; 6-octynyl-; 7-octynyl-; 1-nonylnyl-; 2-nonylnyl-; 3-nonylnyl-; 4-nonylnyl-; 5-nonylnyl-; 6-nonylnyl-; 7-nonylnyl-; 8-nonylnyl-; 1-decynyl-; 2-decynyl-; 3-decynyl-; 4-decynyl-; 5-decynyl-; 6-decynyl-; 7-decynyl-; 8-decynyl-; 9-decynyl-; 1-undecynyl-; 2-undecynyl-; 3-undecynyl-; 4-undecynyl-; 5-undecynyl-; 6-undecynyl-; 7-undecynyl-; 8-undecynyl-; 9-undecynyl-; 10-undecynyl-; 1-dodecynyl-; 2-dodecynyl-; 3-dodecynyl-; 4-dodecynyl-; 5-dodecynyl-; 6-dodecynyl-; 7-dodecynyl-; 8-dodecynyl-; 9-dodecynyl-; 10-dodecynyl-; 11-dodecynyl- groups; and related branched isomers. Preferably, the alkynyl group is a straight chain or branched alkenyl group with 2 to 8 carbon atoms.

The cycloalkyl group can be cycloalkyl groups with 3 to 10 carbon atoms. The cycloalkyl group can be selected from the group consisting of: cyclopropyl-; cyclobutyl-; cyclopentyl-; cyclohexyl-; cycloheptyl-; and cyclooctyl- groups. These groups can be variably substituted at any position(s) around the ring. Preferably, the cycloalkyl group is a cycloalkyl group with 5 to 7 carbon atoms.

The cycloalkenyl group can be cycloalkenyl groups with 3 to 10 carbon atoms. The cycloalkenyl group can be selected from the group consisting of cyclobutenyl-;

cyclopentenyl-; cyclohexenyl-; cycloheptenyl-; and cyclooctenyl- groups that can variably be substituted at any position(s) around the ring. Preferably, the cycloalkenyl group is a cycloalkenyl group with 5 to 7 carbon atoms.

- 5 **The aryl group** can be selected from the group consisting of phenyl; biphenyl; naphthyl; anthracenyl groups; and the like. Preferably, the aryl group is a phenyl group.

10 **The aryl alkyl group** can be a group with 7 to 18 carbons. The aryl alkyl group can be selected from the group consisting of: benzyl-; 1-methylbenzyl-; 2-phenylethyl-; 3-phenylpropyl-; 4-phenylbutyl-; 5-phenylpentyl-; 6-phenylhexyl-; 1-naphthylmethyl; and 2-(1-naphthyl)-ethyl groups; and the like. Preferably, the aryl alkyl group is an aryl alkyl group with 7 to 12 carbon atoms.

15 **The heterocyclic group** can include 5- to 10-membered heterocyclic groups containing nitrogen, oxygen, or sulfur. The heterocyclic ring can be fused with a cyclic or aromatic ring having 3 to 7 carbon atoms such as benzene; cyclopropyl; cyclobutane; cyclopentane; and cyclohexane ring systems. Preferably, the heterocyclic ring has 5 or 6 carbon atoms. The heterocyclic ring can be selected from the group consisting of: furyl-; dihydrofuranyl-; tetrahydrofuranyl-; dioxolanyl-; oxazolyl-; dihydrooxazolyl-; oxazolidinyl-; isoxazolyl-; dihydroisoxazolyl-; isoxazolidinyl-; oxathiolanyl-; thienyl-; tetrahydrothienyl-; dithiolanyl-; thiazolyl-; dihydrothiazolyl-; thiazolidinyl-; isothiazolyl-; dihydroisothiazolyl-; isothiazolidinyl-; pyrrolyl-; dihydropyrrolyl-; pyrrolidinyl-; pyrazolyl-; dihydropyrazolyl-; pyrazolidinyl-; imidazolyl-; dihydroimidazolyl-; imidazolidinyl-; triazolyl-; dihydrotriazolyl-; triazolidinyl-; tetrazolyl-; dihydrotetrazolyl-; tetrazolidinyl-; pyridyl-; dihydropyridyl-; piperidinyl-; morpholinyl-; dioxanyl-; oxathianyl-; trioxanyl-; thiomorpholinyl-; pyridazinyl-; dihydropyridazinyl-; tetrahydropyridazinyl-; hexahydropyridazinyl-; pyrimidinyl-; dihydropyrimidinyl-; tetrahydropyrimidinyl-; hexahydropyrimidinyl-; pyrazinyl-; piperazinyl-; pyranyl-; dihydropyranyl-; tetrahydropyranyl-; thiopyranyl-; dihydrothiopyranyl-; tetrahydrothiopyranyl-; dithianyl-; purinyl-; pyrimidinyl-; pyrrolizinyl-; pyrrolizidinyl-; indolyl-; dihydroindolyl-; isoindolyl-; indolizinyl-; indolizidinyl-; quinolyl-; dihydroquinolyl-; tetrahydroquinolyl-; isoquinolyl-; dihydroquinolyl-; tetrahydroquinolyl-; quinolizinyl-; quinolizidinyl-; phenanthrolinyl-; chromenyl-; chromanyl-; isochromenyl-; isochromanyl-; benzofuranyl-; and carbazolyl- groups; and the like.

35 **The alkoxy group** can be a straight chain or branched alkoxy group having 2-12 carbon

atoms such as methoxy; ethoxy; propyloxy; isopropyloxy; butyloxy; isobutyloxy; tert-butyloxy; pentyloxy; hexyloxy; heptyloxy; or octyloxy.

The alkenyloxy group can be a straight chain or branched alkenyloxy group having 2-12 carbon atoms. The alkenyloxy group can be selected from the group consisting of: ethynyloxy-; 1-propynyloxy-; 2-propynyloxy-; 1-butyloxy-; 2-butyloxy-; 3-butyloxy-; 1-pentyloxy-; 2-pentyloxy-; 3-pentyloxy-; 4-pentyloxy-; 1-hexynyloxy-; 2-hexynyloxy-; 3-hexynyloxy-; 4-hexynyloxy-; 5-hexynyloxy-; 1-heptyloxy-; 2-heptyloxy-; 3-heptyloxy-; 4-heptyloxy-; 5-heptyloxy-; 6-heptyloxy-; 1-octynyloxy-; 2-octynyloxy-; 3-octynyloxy-; 4-octynyloxy-; 5-octynyloxy-; 6-octynyloxy-; 7-octynyloxy-; 1-nonyloxy-; 2-nonyloxy-; 3-nonyloxy-; 4-nonyloxy-; 5-nonyloxy-; 6-nonyloxy-; 7-nonyloxy-; 8-nonyloxy-; 1-decynyloxy-; 2-decynyloxy-; 3-decynyloxy-; 4-decynyloxy-; 5-decynyloxy-; 6-decynyloxy-; 7-decynyloxy-; 8-decynyloxy-; 9-decynyloxy-; 1-undecynyloxy-; 2-undecynyloxy-; 3-undecynyloxy-; 4-undecynyloxy-; 5-undecynyloxy-; 6-undecynyloxy-; 7-undecynyloxy-; 8-undecynyloxy-; 9-undecynyloxy-; 10-undecynyloxy-; 1-dodecynyloxy-; 2-dodecynyloxy-; 3-dodecynyloxy-; 4-dodecynyloxy-; 5-dodecynyloxy-; 6-dodecynyloxy-; 7-dodecynyloxy-; 8-dodecynyloxy-; 9-dodecynyloxy-; 10-dodecynyloxy-; and 11-dodecynyloxy- groups; and related branched isomers. Preferably, the alkenyloxy group is a straight chain or branched alkenyloxy groups with 2 to 8 carbon atoms.

The aryloxy group can be an aryloxy group, such as a phenoxy or naphthyloxy group (e.g.: phenoxy; 2-methylphenoxy; 3-methylphenoxy; 4-methylphenoxy; 2-allylphenoxy; 2-chlorophenoxy; 3-chlorophenoxy; 4-chlorophenoxy; 4-methoxyphenoxy; 2-allyloxyphenoxy; naphthyloxy; and the like). The group can optionally be substituted with an alkyl or alkenyl or alkoxy group having 1 to 4 carbon atoms or halogens.

The aryl alkyloxy group can be benzyloxy or 2-phenylethyloxy.

The alkylamino group can be a straight chain or branched alkylamino group having 2-12 carbon atoms such as: methylamino; ethylamino; propylamino; isopropylamino; butylamino; isobutylamino; tert-butylamino; pentylamino; hexylamino; heptylamino; or octylamino.

The alkenyl amino group can be a straight chain or branched alkenylamino group having 2-12 carbon atoms. The alkenyl amino group can be selected from the group consisting of: ethynylamino-; 1-propynylamino-; 2-propynylamino-; 1-butylnylamino-; 2-butylnylamino-; 3-

butynylamino-; 1-pentynylamino-; 2-pentynylamino-; 3-pentynylamino-; 4-pentynylamino-; 1-hexynylamino-; 2-hexynylamino-; 3-hexynylamino-; 4-hexynylamino-; 5-hexynylamino-; 1-heptynylamino-; 2-heptynylamino-; 3-heptynylamino-; 4-heptynylamino-; 5-heptynylamino-; 6-heptynylamino-; 1-octynylamino-; 2-octynylamino-; 3-octynylamino-; 4-octynylamino-; 5-octynylamino-; 6-octynylamino-; 7-octynylamino-; 1-nonynylamino-; 2-nonynylamino-; 3-nonynylamino-; 4-nonynylamino-; 5-nonynylamino-; 6-nonynylamino-; 7-nonynylamino-; 8-nonynylamino-; 1-decynylamino-; 2-decynylamino-; 3-decynylamino-; 4-decynylamino-; 5-decynylamino-; 6-decynylamino-; 7-decynylamino-; 8-decynylamino-; 9-decynylamino-; 1-undecynylamino-; 2-undecynylamino-; 3-undecynylamino-; 4-undecynylamino-; 5-undecynylamino-; 6-undecynylamino-; 7-undecynylamino-; 8-undecynylamino-; 9-undecynylamino-; 10-undecynylamino-; 1-dodecynylamino-; 2-dodecynylamino-; 3-dodecynylamino-; 4-dodecynylamino-; 5-dodecynylamino-; 6-dodecynylamino-; 7-dodecynylamino-; 8-dodecynylamino-; 9-dodecynylamino-; 10-dodecynylamino-; and 11-dodecynylamino- groups; and related branched isomers. Preferably, the alkenyl amino group is a straight chain or branched alkenylamino group with 2 to 8 carbon atoms.

The **arylamino group** can be an arylamino group such as a phenylamino or naphthylamino group, optionally substituted with an alkyl or alkenyl or alkoxy group having 1 to 4 carbon atoms, or halogens. The arylamino group can be selected from the group consisting of: phenylamino; 2-methylphenylamino; 3-methylphenylamino; 4-methylphenylamino; 2-allylphenylamino; 2-chlorophenylamino; 3-chlorophenylamino; 4-chlorophenylamino; 4-methoxyphenylamino; 2-allyloxyphenylamino; naphthylamino; and the like.

The **arylalkylamino group** can be benzylamino or 2-phenylethylamino.

25

The **alkylthio group** can be an alkylthio group having 1 to 8 carbon atoms. The alkylthio group can be selected from the group consisting of: methylthio; ethylthio; propylthio; butylthio; isobutylthio; and pentylthio.

The **alkenylthio group** can be a straight chain or branched alkenylthio group having 1 to 8 carbon atoms. The alkenylthio group can be selected from the group consisting of: ethynylthio-; 1-propynylthio-; 2-propynylthio-; 1-butynylthio-; 2-butynylthio-; 3-butynylthio-; 1-pentynylthio-; 2-pentynylthio-; 3-pentynylthio-; 4-pentynylthio-; 1-hexynylthio-; 2-hexynylthio-; 3-hexynylthio-; 4-hexynylthio-; 5-hexynylthio-; and the like.

35

The **arylthio group** can be an alkenylthio group having 1 to 8 carbon atoms such as a phenylthio or naphthylthio group, which can optionally be substituted with an alkyl or alkenyl or alkoxy group having 1 to 4 carbon atoms; and also halogens, e.g.: phenylthio; 2-methylphenylthio; 3-methylphenylthio; 4-methylphenylthio; 2-allylphenylthio; 2-chlorophenylthio; 3-chlorophenylthio; 4-chlorophenylthio; 4-methoxyphenylthio; 2-allyloxyphenylthio; naphthylthio; and the like.

The **arylalkylthio group** can be an alkenylthio group having 1 to 8 carbon atoms such as a benzylthio- group or a 2-phenylethylthio-group.

The **alkoxycarbonyl group** can be: methoxycarbonyl; ethoxycarbonyl; or the like.

The **substituted or unsubstituted carbamoyl group** can be: carbamoyl; methylcarbamoyl; dimethylcarbamoyl; diethylcarbamoyl; or the like.

The **acyl group** can be an acyl group with 1 to 8 carbon atoms such as: formyl; acetyl; propionyl; or benzoyl groups; or the like.

The alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aryl alkyl, heterocyclic, alkoxy, alkenyloxy, aryloxy, aryl alkyloxy, alkylamino, alkenylamino, arylamino, arylalkylamino, alkylthio, alkenylthio, arylthio, arylalkylthio, alkoxycarbonyl, substituted and unsubstituted carbamoyl and acyl groups mentioned above can optionally be substituted. Examples of substituents include: halogens (F; Cl; Br; I); hydroxyl groups; mercapto groups; carboxylates; nitro groups; cyano groups; substituted or unsubstituted amino groups (including amino, methylamino, dimethylamino, ethylamino, diethylamino, and various protected amines such as tert-butoxycarbonyl- and arylsulfonamido groups); alkoxy groups (having 1 to 8 carbon atoms such as methoxy, ethoxy, propyloxy, isopropyloxy, butyloxy, isobutyloxy, tert-butyloxy, pentyloxy, hexyloxy, heptyloxy or octyloxy); alkenyloxy groups (having 2 to 8 carbon atoms such as a vinyloxy; allyloxy; 3-butenyloxy or 5-hexenyloxy); aryloxy groups (such as a phenoxy or naphthyloxy group which can be optionally substituted with an alkyl or alkenyl or alkoxy group having 1 to 4 carbon atoms; and also halogens, e.g., phenoxy, 2-methylphenoxy, 3-methylphenoxy, 4-methylphenoxy, 2-allylphenoxy, 2-chlorophenoxy, 3-chlorophenoxy, 4-chlorophenoxy, 4-methoxyphenoxy, 2-allyloxyphenoxy, naphthyloxy, and the like); aryl alkyloxy groups (e.g., benzyloxy and 2-phenylethyloxy); alkylthio groups (having 1 to 8 carbon atoms such as methylthio, ethylthio, propylthio, butylthio, isobutylthio,

pentylthio); alkoxy carbonyl groups (e.g. methoxycarbonyl, ethoxycarbonyl, and the like); substituted or unsubstituted carbamoyl group (e.g. carbamoyl, methylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl and the like); acyl groups (with 1 to 8 carbon atoms such as formyl, acetyl, propionyl, or benzoyl groups); and others.

5

The above-mentioned cycloalkyl, cycloalkenyl, aryl, aryl alkyl, heterocyclic, alkoxy, alkenyloxy, aryloxy, aryl alkyloxy, alkylthio, and alkoxy carbonyl groups can also be substituted with alkyl groups having 1 to 5 carbon atoms, alkenyl groups with 2 to 5 carbon atoms, or haloalkyl groups with 1 to 5 carbon atoms in addition to the substituents specified above.

10

The number of substituents can be one or more than one. The substituents can be the same or different.

15

The R_1 and R_2 groups can be each, independently of each other, be a **functional group**. The functional group is selected from the group consisting of: halo, pseudohalo, hydroxyl, variably substituted mercapto, variably substituted sulfinyl, variably substituted sulfonyl, carboxylates, variably substituted amino, variably substituted amido, variably substituted ureido, variably substituted carbamoyl, and variably substituted urethano. Pseudohalo is

20

nitro, cyano, azido, cyanato, isocyanato, or isothiocyanato.

R_1 and R_2 together can also be present as a saturated or unsaturated optionally substituted carbocycle or a heterocycle having 5 to 12 carbon atoms, such as: cyclopentane; cyclohexane; cyclohexene; cyclohexadiene; cycloheptane; cyclooctane; cyclononane; or

25

cyclodecane.

As used herein, a "variably substituted" group is a group that is unsubstituted or is substituted with one or more, in another embodiment one to five, in another embodiment one, two or three, substituents.

30

"Polypeptide" and "protein" are used interchangeably and mean any peptide-linked chain of amino acids, regardless of length or post-translational modification. The invention also features yeast derived enantioselective 2,2-disubstituted epoxide hydrolase (YEDH) polypeptides with conservative substitutions. Conservative substitutions typically include

35

substitutions within the following groups: glycine and alanine; valine, isoleucine, and

leucine; aspartic acid and glutamic acid; asparagine, glutamine, serine and threonine; lysine, histidine and arginine; and phenylalanine and tyrosine.

The term "isolated" polypeptide or peptide fragment, as used herein, refers to a polypeptide or a peptide fragment which either has no naturally-occurring counterpart or has been separated or purified from components which naturally accompany it, e.g., microorganism cellular components such as yeast cell cellular components. Typically, the polypeptide or peptide fragment is considered "isolated" when it is at least 70%, by dry weight, free from the proteins and other naturally-occurring organic molecules with which it is naturally associated. Preferably, a preparation of a polypeptide (or peptide fragment thereof) of the invention is at least 80%, more preferably at least 90%, and most preferably at least 99%, by dry weight, the polypeptide (or the peptide fragment thereof), respectively, of the invention. Thus, for example, a preparation of polypeptide x is at least 80%, more preferably at least 90%, and most preferably at least 99%, by dry weight, polypeptide x. Since a polypeptide that is chemically synthesized is, by its nature, separated from the components that naturally accompany it, the synthetic polypeptide is "isolated."

An isolated polypeptide (or peptide fragment) of the invention can be obtained, for example, by: extraction from a natural source (e.g., from yeast cells); expression of a recombinant nucleic acid encoding the polypeptide; or chemical synthesis. A polypeptide that is produced in a cellular system different from the source from which it naturally originates is "isolated," because it will necessarily be free of components which naturally accompany it. The degree of isolation or purity can be measured by any appropriate method, e.g., column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.

An "isolated DNA" is either (1) a DNA that contains sequence not identical to that of any naturally occurring sequence, or (2), in the context of a DNA with a naturally-occurring sequence (e.g., a cDNA or genomic DNA), a DNA free of at least one of the genes that flank the gene containing the DNA of interest in the genome of the organism in which the gene containing the DNA of interest naturally occurs. The term therefore includes a recombinant DNA incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote. The term also includes a separate molecule such as: a cDNA (e.g., SEQ ID NOs: 8, 9, 10, 11, 12, 13, or 14) where the corresponding genomic DNA has introns and therefore a different sequence; a genomic fragment that lacks at least one of the flanking genes; a fragment of cDNA or genomic DNA

produced by polymerase chain reaction (PCR) and that lacks at least one of the flanking genes; a restriction fragment that lacks at least one of the flanking genes; a DNA encoding a non-naturally occurring protein such as a fusion protein, mutein, or fragment of a given protein; and a nucleic acid which is a degenerate variant of a cDNA or a naturally occurring nucleic acid. In addition, it includes a recombinant nucleotide sequence that is part of a hybrid gene, i.e., a gene encoding a non-naturally occurring fusion protein. Also included is a recombinant DNA that includes a portion of SEQ ID NOs: 8-14. It will be apparent from the foregoing that isolated DNA does not mean a DNA present among hundreds to millions of other DNA molecules within, for example, cDNA or genomic DNA libraries or genomic DNA restriction digests in, for example, a restriction digest reaction mixture or an electrophoretic gel slice.

As used herein, a "functional fragment" of a YEDH polypeptide is a fragment of the polypeptide that is shorter than the full-length polypeptide and has at least 20% (e.g., at least: 30%; 40%; 50%; 60%; 70%; 80%; 90%; 95%; 98%; 99%; 100%, or more) of the ability of the full-length polypeptide to enantioselectively hydrolyse a TDE of interest. Fragments of interest can be made by either recombinant, synthetic, or proteolytic digestive methods and tested for their ability to enantioselectively hydrolyse a TDE.

As used herein, "operably linked" means incorporated into a genetic construct so that an expression control sequence effectively controls expression of a coding sequence of interest.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. In case of conflict, the present document, including definitions, will control. Preferred methods and materials are described below, although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. The materials, methods, and examples disclosed herein are illustrative only and not intended to be limiting.

Other features and advantages of the invention, e.g., TDE and DVD substantially enriched for one optical enantiomer, will be apparent from the following description, from the drawings and from the claims.

The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

5

DESCRIPTION OF DRAWINGS

Fig. 1 is schematic depiction of the reactions catalyzed by YEDH using racemic mixtures of two exemplary 2,2-disubstituted epoxides (of general formula (I)) and resulting in optically active epoxides and vicinal diols.

10 Figs. 2A to 10B are line graphs showing the hydrolysis of ($\pm$)-2-methyl-1,2-epoxyheptane by the indicated yeast strains to produce optically active (S)-2-methyl-1,2-epoxyheptane and/or (R)-2-methyl-1,2-heptanediol. The A panel in each figure is a line graph showing the change in concentrations of the epoxide and diol enantiomers with time and the B panel in each figure is a line graph showing the enantiomeric excess of the epoxide and diol at
15 different conversions.

Figs. 11A and 11B are line graphs showing the hydrolysis of ($\pm$)-2-methyl-1,2-epoxyheptane by the indicated yeast strain to produce optically active (R)-2-methyl-1,2-epoxyheptane and/or (S)-2-methyl-1,2-heptanediol. The A and B panels are as indicated for Figs. 2A to 10B.

20 Figs. 12A and 12B are line graphs showing the hydrolysis of ($\pm$)-2-methyl-3-phenyl-1,2-epoxypropane by the indicated yeast strain to produce optically active (S)-2-methyl-3-phenyl-1,2-epoxypropane and/or (R)-2-methyl-3-phenyl-1,2-propanediol. The A and B panels are as indicated for Figs. 2A to 10B.

Figs. 13A to 14B are line graphs showing the hydrolysis of ($\pm$)-2-methyl-3-phenyl-1,2-
25 epoxypropane by the indicated yeast strains to produce optically active (R)-2-methyl-3-phenyl-1,2-epoxypropane and/or (S)-2-methyl-3-phenyl-1,2-propanediol. The A and B panels are as indicated for Figs. 2A to 10B.

Fig. 15 is a line graph showing the hydrolysis of ($\pm$)-2-methyl-3-phenyl-1,2-epoxypropane by the indicated yeast cultivated in a 10 l fermenter to produce optically active (S)- 2-methyl-3-
30 phenyl-1,2-epoxypropane and/or (R)-2-methyl-3-phenyl-1,2-propanediol. The graph shows the change in concentrations of the epoxide and diol enantiomers with time.

Figs. 16, 17, and 18 are line graphs showing the hydrolysis of ($\pm$)-2-methyl-3-phenyl-1,2-epoxypropane by yeast host strains transformed with vectors expressing YEDH from selected wild type yeast strains to produce optically active (S)- 2-methyl-3-phenyl-1,2-
35 epoxypropane and/or (R)-2-methyl-3-phenyl-1,2-propanediol. The graphs show the change

in concentrations of the epoxide and diol enantiomers with time.

Figs. 19A and 19B are line graphs showing the hydrolysis of ($\pm$)-2-methyl-3-phenyl-1,2-epoxypropane using whole cells (Fig. 19 A) and a crude enzyme preparation (Fig. 19B) obtained from the host *Yarrowia lipolytica* expressing the epoxide hydrolase derived from
5 *Rhodotorula araucariae* NCYC 3183 (YL 25 TsA). This experiment demonstrates that whole cells or enzyme preparations can be used to catalyze the reactions.

Fig. 20 is a restriction map of the pYLHmA (pINA1291) expression vector. The positions of the hp4d promoter and LIP2 terminator and of unique restriction sites available for the insertion of coding sequences are indicated.

10 Fig. 21 is a restriction map of the pYLTsA (pINA3313) expression vector. The positions of the TEF promoter and LIP2 terminator and of unique restriction sites available for the insertion of coding sequences are indicated.

Fig. 22 is a depiction of the amino acid sequence (SEQ ID NO:1) of a YEDH polypeptide encoded by cDNA derived from a *Rhodospiridium toruloides* strain (assigned accession no.
15 NCYC 3181).

Fig. 23 is a depiction of the amino acid sequence (SEQ ID NO:2) of a YEDH polypeptide encoded by cDNA derived from a *Rhodospiridium toruloides* strain (assigned identification no. UOFS Y-0471).

Fig. 24 is a depiction of the amino acid sequence (SEQ ID NO:3) of a YEDH polypeptide
20 encoded by cDNA derived from a *Rhodotorula araucariae* strain (assigned accession no. NCYC 3183).

Fig. 25 is a depiction of the amino acid sequence (SEQ ID NO:4) of a YEDH polypeptide encoded by cDNA derived from a *Cryptococcus curvatus* strain (assigned accession no. NCYC 3158).

25 Fig. 26 is a depiction of the amino acid sequence (SEQ ID NO:5) of a YEDH polypeptide encoded by cDNA derived from a *Rhodospiridium paludigenum* (assigned accession no. NCYC 3179).

Fig. 27 is a depiction of the amino acid sequence (SEQ ID NO:6) of a YEDH polypeptide encoded by cDNA derived from a *Debaromyces hansenii* (assigned accession no. NCYC
30 3167).

Fig. 28 is a depiction of the partial amino acid sequence (SEQ ID NO:7) of a YEDH polypeptide encoded by cDNA derived from a *Rhodotorula minuta* var. *minuta* (assigned accession no. UOFS Y-0835).

Fig. 29 is a depiction of the nucleotide sequence (SEQ ID NO:8) of a YEDH polypeptide-
35 encoding cDNA derived from a *Rhodospiridium toruloides* strain (assigned accession no.

NCYC 3181).

Fig. 30 is a depiction of the nucleotide sequence (SEQ ID NO:9) of a YEDH polypeptide-encoding cDNA derived from a *Rhodospiridium toruloides* strain (assigned identification no. UOFS Y-0471).

5 Fig. 31 is a depiction of the nucleotide sequence (SEQ ID NO:10) of a YEDH polypeptide-encoding cDNA derived from a *Rhodotorula araucariae* strain (assigned accession no. NCYC 3183).

10 Fig. 32 is a depiction of the nucleotide sequence (SEQ ID NO:11) of a YEDH polypeptide-encoding cDNA derived from a *Cryptococcus curvatus* strain (assigned accession no. NCYC 3158).

Fig. 33 is a depiction of the nucleotide sequence (SEQ ID NO:12) of a YEDH polypeptide-encoding cDNA derived from a *Rhodospiridium paludigenum* (assigned accession no. NCYC 3179).

15 Fig. 34 is a depiction of the nucleotide sequence (SEQ ID NO:13) of a YEDH polypeptide-encoding cDNA derived from a *Debaromyces hansenii* (assigned accession no. NCYC 3167).

Fig. 35 is a depiction of the partial nucleotide sequence (SEQ ID NO:14) of a YEDH polypeptide-encoding cDNA derived from a *Rhodotorula minuta* var. *minuta* (assigned accession no. UOFS Y-0835).

20 Fig. 36 is a table showing the homology at the amino acid level of the YEDH polypeptides with SEQ ID NOs: 1-6.

Fig. 37 is a table showing the homology at the nucleotide level of YEDH-encoding cDNA molecules with SEQ ID NOs: 8-13.

25 Fig. 38 is a depiction of the amino acid sequences of eight enantioselective epoxide hydrolases aligned for maximum homology. Also shown are consensus amino acids. The sequences labeled #1, #46, #25, Car054, and #692 correspond to SEQ ID NOs: 1-5 and the sequences labeled #23, Jen46-2 and # 777 correspond to enantioselective hydrolases catalyzing the hydrolysis of non-TDE epoxides. The consensus catalytic triad is composed of a nucleophile, an acid and a base, the positions of which are indicated by N, A and B, respectively. "HGXP" represents the region of the oxy-anion hole of the enzyme. "sxNxss" represents the genetic motif found in α/β -hydrolase fold enzymes. (= homology; P = identity of 75-100%; P = identity of 50-75%; . = gap).

30

DETAILED DESCRIPTION

Various aspects of the invention are described below.

5 Nucleic Acid Molecules

10 The YEDH nucleic acid molecules of the invention can be cDNA, genomic DNA, synthetic DNA, or RNA, and can be double-stranded or single-stranded (i.e., either a sense or an antisense strand). Segments of these molecules are also considered within the scope of the invention, and can be produced by, for example, the polymerase chain reaction (PCR) or generated by treatment with one or more restriction endonucleases. A ribonucleic acid (RNA) molecule can be produced by *in vitro* transcription. Preferably, the nucleic acid molecules encode polypeptides that, regardless of length, are soluble under normal physiological conditions.

15 The nucleic acid molecules of the invention can contain naturally occurring sequences, or sequences that differ from those that occur naturally, but, due to the degeneracy of the genetic code, encode the same polypeptide (for example, one the polypeptides with SEQ ID NOS:1 - 7). In addition, these nucleic acid molecules are not limited to coding sequences, e.g., they can include some or all of the non-coding sequences that lie upstream or downstream from a coding sequence.

25 The nucleic acid molecules of the invention can be synthesized (for example, by phosphoramidite-based synthesis) or obtained from a biological cell, such as the cell of a eukaryote (e.g., a mammal such as human or a mouse or a yeast such as any of the genera, species, and strains of yeast disclosed herein) or a prokaryote (e.g., a bacterium such as *Escherichia coli*). The nucleic acids can be those of a yeast such as any of the genera, species, and strains of yeast disclosed herein. Combinations or modifications of the nucleotides within these types of nucleic acids are also encompassed.

30 In addition, the isolated nucleic acid molecules of the invention encompass segments that are not found as such in the natural state. Thus, the invention encompasses recombinant nucleic acid molecules (for example, isolated nucleic acid molecules encoding the polypeptides of SEQ ID NOS: 1- 7) incorporated into a vector (for example, a plasmid or viral vector) or into the genome of a heterologous cell (or the genome of a homologous cell,

35

at a position other than the natural chromosomal location). Recombinant nucleic acid molecules and uses thereof are discussed further below.

Techniques associated with detection or regulation of genes are well known to skilled artisans. Such techniques can be used, for example, to test for expression of a YEDH gene in a test cell (e.g. a yeast cell) of interest.

A YEDH family gene or protein can be identified based on its similarity to the relevant YEDH gene or protein, respectively. For example, the identification can be based on sequence identity. The invention features isolated nucleic acid molecules which are, or are at least 50% (e.g., at least: 55%; 60%; 65%; 75%; 85%; 95%; 98%; or 99%) identical to: (a) a nucleic acid molecule that encodes the polypeptide of SEQ ID NOs: 1-7; (b) the nucleotide sequence of SEQ ID NOs: 8-14; (c) a nucleic acid molecule which includes a segment of at least 15 (e.g., at least: 20; 25; 30; 35; 40; 50; 60; 80; 100; 125; 150; 175; 200; 250; 300; 350; 400; 500; 600; 700; 800; 900; 1,000; 1,100; 1,200; 1,220; 1,225; 1,228; 1,230; 1,231; 1,232; 1,233; 1,234; 1,235; or 1,236) nucleotides of SEQ ID NOs: 8-14; (d) a nucleic acid molecule encoding any of the polypeptides or fragments thereof disclosed below; and (e) the complement of any of the above nucleic acid molecules. The complements of the above molecules can be full-length complements or segment complements containing a segment of at least 15 (e.g., at least: 20; 25; 30; 35; 40; 50; 60; 80; 100; 125; 150; 175; 200; 250; 300; 350; 400; 500; 600; 700; 800; 900; 1,000; 1,100; 1,200; 1,220; 1,225; 1,228; 1,230; 1,231; 1,232; 1,233; 1,234; 1,235; or 1,236) consecutive nucleotides complementary to any of the above nucleic acid molecules. Identity can be over the full-length of SEQ ID NOs: 8-14 or over one or more contiguous or non-contiguous segments.

The determination of percent identity between two sequences is accomplished using the mathematical algorithm of Karlin and Altschul, *Proc. Natl. Acad. Sci. USA* 90, 5873-5877, 1993. Such an algorithm is incorporated into the BLASTN and BLASTP programs of Altschul *et al.* (1990) *J. Mol. Biol.* 215, 403-410. BLAST nucleotide searches are performed with the BLASTN program, score = 100, wordlength = 12, to obtain nucleotide sequences homologous to YEDH-encoding nucleic acids. BLAST protein searches are performed with the BLASTP program, score = 50, wordlength = 3, to obtain amino acid sequences homologous to the YEDH polypeptide. To obtain gapped alignments for comparative purposes, Gapped BLAST is utilized as described in Altschul *et al.* (1997) *Nucleic Acids*

Res. 25, 3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) are used.

Hybridization can also be used as a measure of homology between two nucleic acid sequences. A YEDH-encoding nucleic acid sequence, or a portion thereof, can be used as a hybridization probe according to standard hybridization techniques. The hybridization of a YEDH probe to DNA or RNA from a test source (e.g., a mammalian cell) is an indication of the presence of YEDH DNA or RNA in the test source. Hybridization conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y., 6.3.1-6.3.6, 1991. Moderate hybridization conditions are defined as equivalent to hybridization in 2X sodium chloride/sodium citrate (SSC) at 30°C, followed by a wash in 1 X SSC, 0.1% SDS at 50°C. Highly stringent conditions are defined as equivalent to hybridization in 6X sodium chloride/sodium citrate (SSC) at 45°C, followed by a wash in 0.2 X SSC, 0.1% SDS at 65°C.

The invention also encompasses: (a) vectors (see below) that contain any of the foregoing YEDH coding sequences (including coding sequence segments) and/or their complements (that is, "antisense" sequences); (b) expression vectors that contain any of the foregoing YEDH coding sequences (including coding sequence segments) operably linked to one or more transcriptional and/or translational regulatory elements (TRE; examples of which are given below) necessary to direct expression of the coding sequences; (c) expression vectors encoding, in addition to a YEDH polypeptide (or a fragment thereof), a sequence unrelated to YEDH, such as a reporter, a marker, or a signal peptide fused to YEDH; and (d) genetically engineered host cells (see below) that contain any of the foregoing expression vectors and thereby express the nucleic acid molecules of the invention.

Recombinant nucleic acid molecules can contain a sequence encoding a YEDH polypeptide or a YEDH polypeptide having an heterologous signal sequence. The full length YEDH polypeptide, or a fragment thereof, can be fused to such heterologous signal sequences or to additional polypeptides, as described below. Similarly, the nucleic acid molecules of the invention can encode the mature form of a YEDH or a form that includes an exogenous polypeptide that facilitates secretion.

The TRE referred to above and further described below include but are not limited to inducible and non-inducible promoters, enhancers, operators and other elements that are

known to those skilled in the art and that drive or otherwise regulate gene expression. Such regulatory elements include but are not limited to the cytomegalovirus hCMV immediate early gene, the early or late promoters of SV40 adenovirus, the *lac* system, the *trp* system, the *TAC* system, the *TRC* system, the major operator and promoter regions of phage A, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase, the promoters of acid phosphatase, and the promoters of the yeast α -mating factors. Other useful TRE are listed in the examples below.

Similarly, the nucleic acid can form part of a hybrid gene encoding additional polypeptide sequences, for example, a sequence that functions as a marker or reporter. Examples of marker and reporter genes include β -lactamase, chloramphenicol acetyltransferase (CAT), adenosine deaminase (ADA), aminoglycoside phosphotransferase (neo^r , $G418^r$), dihydrofolate reductase (DHFR), hygromycin-B-phosphotransferase (HPH), thymidine kinase (TK), *lacZ* (encoding β -galactosidase), and xanthine guanine phosphoribosyltransferase (XGPRT), and green, blue, or yellow fluorescent protein. As with many of the standard procedures associated with the practice of the invention, skilled artisans will be aware of additional useful reagents, for example, additional sequences that can serve the function of a marker or reporter. Generally, the hybrid polypeptide will include a first portion and a second portion; the first portion being a YEDH polypeptide (or any of YEDH fragments described below) and the second portion being, for example, the reporter described above or an Ig heavy chain constant region or part of an Ig heavy chain constant region, e.g., the CH2 and CH3 domains of IgG2a heavy chain. Other hybrids could include an antigenic tag or a poly-His tag to facilitate purification.

The expression systems that can be used for purposes of the invention include, but are not limited to, microorganisms such as yeasts (e.g., any of the genera, species or strains listed herein) or bacteria (for example, *E. coli* and *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA, or cosmid DNA expression vectors containing the nucleic acid molecules of the invention; yeast (for example, *Saccharomyces*, *Kluyveromyces*, *Hansenula*, *Pichia*, *Yarrowia*, *Arxula*, *Candida*, and other genera, species, and strains listed herein) transformed with recombinant yeast expression vectors containing the nucleic acid molecule of the invention; insect cell systems infected with recombinant virus expression vectors (for example, baculovirus) containing the nucleic acid molecule of the invention; plant cell systems infected with recombinant virus expression vectors (for example, cauliflower mosaic virus (CaMV) or tobacco mosaic virus (TMV)) or transformed

with recombinant plasmid expression vectors (for example, Ti plasmid) containing a YEDH nucleotide sequence; or mammalian cell systems (for example, COS, CHO, BHK, 293, VERO, HeLa, MDCK, WI38, and NIH 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (for example, the metallothionein promoter) or from mammalian viruses (for example, the adenovirus late promoter and the vaccinia virus 7.5K promoter). Also useful as host cells are primary or secondary cells obtained directly from a mammal and transfected with a plasmid vector or infected with a viral vector.

The invention includes wild-type and recombinant cells including, but not limited to, yeast cells (e.g., any of those disclosed herein) containing any of the above YEDH genes, nucleic acid molecules, and genetic constructs. Other cells that can be used as host cells are listed herein. The cells are preferably isolated cells. As used herein, the term "isolated" as applied to a microorganism (e.g., a yeast cell) refers to a microorganism which either has no naturally-occurring counterpart (e.g., a recombinant microorganism such as a recombinant yeast) or has been extracted and/or purified from an environment in which it naturally occurs. Thus, an "isolated microorganism" does not include one residing in an environment in which it naturally occurs, for example, in the air, outer space, the ground, oceans, lakes, rivers, and streams and the like, ground at the bottom of oceans, lakes, rivers, and streams and the like, snow, ice on top of the ground or in/on oceans lakes, rivers, and streams and the like, man-made structures (e.g., buildings), or in natural hosts (e.g., plant, animal or microbial hosts) of the microorganism, unless the microorganism (or a progenitor of the microorganism) was previously extracted and or purified from an environment in which it naturally occurs and subsequently returned to such an environment or any other environment in which it can survive. An example of an isolated microorganism is one in a substantially pure culture of the microorganism.

Moreover the invention provides a substantially pure culture of a microorganism (e.g., a microbial cell such as a yeast cell). As used herein, a "substantially pure culture" of a microorganism is a culture of that microorganism in which less than about 40% (i.e., less than about : 35%; 30%; 25%; 20%; 15%; 10%; 5%; 2%; 1%; 0.5%; 0.25%; 0.1%; 0.01%; 0.001%; 0.0001%; or even less) of the total number of viable microbial cells (bacterial, fungal (including yeast), mycoplasmal, or protozoan cells) in the culture are viable microbial cells other than the microorganism. The term "about" in this context means that the relevant percentage can be 15% percent of the specified percentage above or below the

specified percentage. Thus, for example, about 20% can be 17% to 23%. Such a culture of microorganisms includes the microorganisms and a growth, storage, or transport medium. Media can be liquid, semi-solid (e.g., gelatinous media), or frozen. The culture includes the cells growing in the liquid or in/on the semi-solid medium or being stored or transported in a storage or transport medium, including a frozen storage or transport medium. The cultures are in a culture vessel or storage vessel or substrate (e.g., a culture dish, flask, or tube or a storage vial or tube).

The microbial cells of the invention can be stored, for example, as frozen cell suspensions, e.g. in buffer containing a cryoprotectant such as glycerol or sucrose, as lyophilized cells. Alternatively, they can be stored, for example, as dried cell preparations obtained, e.g., by fluidised bed drying or spray drying, or any other suitable drying method. Similarly the enzyme preparations can be frozen, lyophilised, or immobilized and stored under appropriate conditions to retain activity.

Polypeptides and Polypeptide Fragments

The YEDH polypeptides of the invention include all the YEDH polypeptides and fragments of YEDH polypeptides disclosed herein. They can be, for example, the polypeptides with SEQ ID NOs:1-7 and functional fragments of these polypeptides. The polypeptides embraced by the invention also include fusion proteins that contain either full-length or a functional fragment of it fused to unrelated amino acid sequence. The unrelated sequences can be additional functional domains or signal peptides.

The invention features isolated polypeptides which are, or are at least 50% (e.g., at least: 55%; 60%; 65%; 75%; 85%; 95%; 98%; or 99%) identical to the polypeptides with SEQ ID NOs: 1-7. The identity can be over the full-length of the latter polypeptides or over one or more contiguous or non-contiguous segments.

Fragments of YEDH polypeptides are segments of the full-length YEDH polypeptides that are shorter than full-length YEDH polypeptides. Fragments of YEDH polypeptides can contain 5-410 (e.g., 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150, 250, 300, 350, 400, 405, 406, 407, 408, or 409) amino acids of SEQ ID NOs:1-7. Fragments of YEDH can be functional fragments or antigenic fragments.

The polypeptides can be any of those described above but with not more than 50 (e.g., not more than 50, 45, 40, 35, 30, 25, 20, 17, 14, 12, 10, nine, eight, seven, six, five, four, three, two, or one) conservative substitution(s). Such substitutions can be made by, for example, site-directed mutagenesis or random mutagenesis of appropriate YEDH coding sequences.

5

"Functional fragments" of a YEDH polypeptide (and, optionally, any of the above-described YEDH polypeptide variants) have at least 20% (e.g., 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, 100%, or more) of the ability of the full-length, wild-type YEDH polypeptide to enantioselectively hydrolyse a TDE of interest. One of skill in the art will be able to predict YEDH functional fragments using his or her own knowledge and information provided herein, e.g., the amino acids alignments in Fig. 38 showing highly conserved domains as well and residues required for function of epoxide hydrolase activity.

10

15

Fragments of interest can be made either by recombinant, synthetic, or proteolytic digestive methods and tested for their ability to enantioselectively hydrolyse a TDE.

Antigenic fragments of the polypeptides of the invention are fragments that can bind to an antibody. Methods of testing whether a fragment of interest can bind to an antibody are known in the art.

20

The polypeptides can be purified from natural sources (e.g., wild-type or recombinant yeast cells such as any of those described herein). Smaller peptides (e.g., those less than about 100 amino acids in length) can also be conveniently synthesized by standard chemical means. In addition, both polypeptides and peptides can be produced by standard *in vitro* recombinant DNA techniques and *in vivo* transgenesis, using nucleotide sequences encoding the appropriate polypeptides or peptides. Methods well-known to those skilled in the art can be used to construct expression vectors containing relevant coding sequences and appropriate transcriptional/translational control signals. See, for example, the techniques described in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual* (2nd Ed.) [Cold Spring Harbor Laboratory, N.Y., 1989], and Ausubel *et al.*, *Current Protocols in Molecular Biology* [Green Publishing Associates and Wiley Interscience, N.Y., 1989].

25

30

35

Polypeptides and fragments of the invention also include those described above, but modified by the addition, at the amino- and/or carboxyl-terminal ends, of a blocking agent to facilitate survival of the relevant polypeptide. This can be useful in those situations in which

the peptide termini tend to be degraded by proteases. Such blocking agents can include, without limitation, additional related or unrelated peptide sequences that can be attached to the amino and/or carboxyl terminal residues of the peptide to be administered. This can be done either chemically during the synthesis of the peptide or by recombinant DNA
5 technology by methods familiar to artisans of average skill.

Alternatively, blocking agents such as pyroglutamic acid or other molecules known in the art can be attached to the amino and/or carboxyl terminal residues, or the amino group at the amino terminus or carboxyl group at the carboxyl terminus can be replaced with a different
10 moiety. Likewise, the peptides can be covalently or noncovalently coupled to pharmaceutically acceptable "carrier" proteins prior to administration.

Also of interest are peptidomimetic compounds that are designed based upon the amino acid sequences of the functional peptide fragments. Peptidomimetic compounds are
15 synthetic compounds having a three-dimensional conformation (i.e., a "peptide motif") that is substantially the same as the three-dimensional conformation of a selected peptide. The peptide motif provides the peptidomimetic compound with the ability to enantioselectively hydrolyse a TDE of interest in a manner qualitatively identical to that of the YEDH functional fragment from which the peptidomimetic was derived. Peptidomimetic compounds can
20 have additional characteristics that enhance their therapeutic utility, such as increased cell permeability and prolonged biological half-life.

The peptidomimetics typically have a backbone that is partially or completely non-peptide, but with side groups that are identical to the side groups of the amino acid residues that
25 occur in the peptide on which the peptidomimetic is based. Several types of chemical bonds, e.g., ester, thioester, thioamide, retroamide, reduced carbonyl, dimethylene and ketomethylene bonds, are known in the art to be generally useful substitutes for peptide bonds in the construction of protease-resistant peptidomimetics.

The invention also provides compositions and preparations containing one or more (e.g., two, three, four, five, six, seven, eight, nine, ten, 12, 15, 20, 25, or more) of the above-described polypeptides, polypeptide variants, and polypeptide fragments. The composition or preparation can be, for example a crude cell (e.g., yeast cell) extract or culture supernatant, a crude enzyme preparation, a highly purified enzyme preparation. The
35 compositions and preparations can also contain one or more of a variety of carriers or

stabilizers known in the art. Carriers and stabilizers are known in the art and include, for example: buffers, such as phosphate, citrate, and other non-organic acids; antioxidants such as ascorbic acid; low molecular weight (less than 10 residues) polypeptides; proteins such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as ethylenediaminetetraacetic acid (EDTA); sugar alcohols such as mannitol, or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween, and Pluronics.

Methods of Producing Optically Active Epoxides and Optically Active Vicinal Diols

The invention provides methods for obtaining enantiopure, or substantially enantiopure, optically active TDE and DVD. Enantiopure optically active TDE or DVD preparations are preparations containing one enantiomer of the TDE or DVD and none of the other enantiomer of the TDE or DVD. "Substantially enantiopure" optically active TDE or DVD preparations are preparations containing at least 55% (e.g., at least: 60%; 70%; 80%; 85%; 90%; 95%; 97%; 98%; 99%; 99.5%; 99.8%; or 99.9%), relative to the total amount of both TDE or DVD enantiomers, of the particular enantiomer of the TDE or the DVD.

The method involves exposing a TDE enantiomeric mixture to a YEDH polypeptide, e.g., by culturing or incubating the mixtures with an isolated YEDH polypeptide or a cell (wild-type or recombinant) that expresses the polypeptide. This exposure can have a variety of outcomes that depend on variables such as, without limitation, the YEDH itself, the chemical nature of the TDE, and, to a lesser extent, the reaction conditions.

First, the YEDH polypeptide can catalyse the conversion of only one of the two TDE enantiomers in the mixture to its corresponding DVD enantiomer. Alternatively, it can catalyse the conversion of one of the two TDE enantiomers in the mixture to its corresponding DVD enantiomer at a much more rapid rate than the other TDE enantiomer to its corresponding DVD. YEDH with such selective activity are designated "enantioselective" and catalyse the "classical" kinetic resolution of a mixture of TDE enantiomers. Such a YEDH polypeptide can catalyse, for example, the conversion of a (R)-TDE (in the TDE enantiomeric mixture) to its corresponding (R)-DVD. During such a reaction, the concentration of the selected TDE enantiomer decreases, the concentration of

the unselected TDE remains constant or decreases at a much slower rate (i.e., the concentration of the unselected TDE increases relative to the concentration of the selected TDE in the mixture); the DVD corresponding to the selected TDE is produced, and the DVD corresponding to the unselected TDE is not produced or is produced at a much lower rate than that the DVD corresponding to the selected TDE. Examples of such reactions include those shown in Figs. 3, 6, 13, and 19. These reactions are of course useful for the enrichment, and hence the production, of a desired TDE enantiomer and/or the production of a desired DVD enantiomer.

In addition, a YEDH polypeptide can catalyse, under certain defined reaction conditions, the conversion of both enantiomers of a TDE to a single DVD. Such YEDH hydrolyse each TDE enantiomer with opposite regioselectivity (i.e., the attack of water occurs at different carbons of the epoxide ring for each of the TDE enantiomers) and are termed "regiospecific" for each TDE enantiomer. Such YEDH are said to catalyse the "enantioconvergent" hydrolysis of a mixture of TDE enantiomers. The YEDH can also have significant selectivity for one enantiomer of the TDE. Where the YEDH has such TDE enantiomeric selectivity, the DVD enantiomer produced has the same chirality as the TDE for which the YEDH polypeptide is selective; for example, if the YEDH polypeptide is selective for an (S)-TDE enantiomer, the DVD enantiomer produced from both TDE enantiomers will be the (S)-DVD enantiomer. Examples of such reactions include those shown in Figs. 9 and 11. During these reactions, there is a decrease in the concentrations of both TDE enantiomers (with the concentration of one decreasing faster than the other if the YDEH polypeptide has TDE enantiomeric selectivity) and the production of one DVD enantiomer. Such reactions are particularly useful for the production of a desired DVD enantiomer and, where the YEDH is significantly TDE enantioselective, they can also be useful for the enrichment and hence the production of a particular TDE enantiomer. The degree of the latter enrichment can be enhanced by, for example, stopping a reaction at a time when the concentration of the selected TDE has significantly decreased and that of the unselected TDE enantiomer is still relatively high.

In yet other reaction types, the YEDH polypeptide can catalyse, for example: (a) the conversion of one TDE enantiomer its corresponding DVD enantiomer and the other TDE enantiomer to both DVD enantiomers; or (b) the conversion of both TDE enantiomers to both DVD enantiomers. Naturally, such reactions, if the YEDH polypeptides employed have no enantioselectivity, would not be useful for the production of a desired TDE enantiomer or

a desired DVD enantiomer. On the other hand, where the YEDH polypeptide has significant selectivity for one TDE enantiomer, the reaction can be used for the production of: (a) the corresponding DVD enantiomer; and (b) the unselected TDE enantiomer. This can be done, as described above, by, e.g., stopping a reaction at a time, or at times, at which the concentration of the desired TDE enantiomer (relative to the total TDE concentration) and/or the concentration of the desired DVD enantiomer (relative to the total DVD concentration) are higher than those of the undesired TDE enantiomer and/or the undesired DVD enantiomer, respectively. In situations where a YEDH polypeptide catalyses the conversion of one TDE enantiomer to both DVD enantiomers, advantage can also be taken of the fact that generally the production of one DVD enantiomer (e.g., one with the chirality corresponding to that of a selected TDE) is favored over the enantiomer.

A YEDH polypeptide useful for the invention is one that hydrolyses one enantiomer of a TDE, and/or effects the production of one enantiomer of a DVD, with less than 80% (e.g., less than: 70%; 60%; 50%; 40%; 30%; 20%; 10%; 5%; 2.5%; 1%; 0.5%; 0.25%; 0.01%, or less), or even none, of the efficiency (as measured by reaction rate) with which it hydrolyses the other TDE enantiomer and/or effects the production of the other DVD enantiomer, respectively.

Useful concentrations of the TDE and conditions of incubation will vary from one YEDH polypeptide to another and from one TDE to another. Given the teachings of the working examples contained herein, one skilled in the art will know how to select working conditions for the production of a desired enantiomer of a desired DVD and/or TDE.

The method can be implemented by, for example, incubating (culturing) the TDE enantiomeric mixtures with a wild-type yeast cell or a recombinant cell (yeast or any other host species listed herein) containing a nucleic acid sequence (e.g. a gene, or a recombinant nucleic acid sequence) encoding a YEDH, a crude extract from such cells, a semi-purified preparation of a YEDH polypeptide, or, for example an isolated YEDH polypeptide. As used herein, "incubating and "culturing" include growing cells and maintaining them in a resting state.

The strain of the yeast cell can be selected from but are not limited to, the following exemplary genera: *Arxula*, *Brettanomyces*, *Bullera*, *Bulleromyces*, *Candida*, *Cryptococcus*, *Debaryomyces*, *Dekkera*, *Exophiala*, *Geotrichum*, *Hormonema*, *Issatchenkia*,

Kluyveromyces, *Lipomyces*, *Mastigomyces*, *Myxozyma*, *Pichia*, *Rhodospiridium*, *Rhodotorula*, *Sporidiobolus*, *Sporobolomyces*, *Trichosporon*, *Wingea*, and *Yarrowia*.

- 5 Yeast strains innately capable of producing a polypeptide which converts or hydrolyses mixtures of TDE enantiomers to optically active (S)-TDE and/or (R)-DVD include the following exemplary yeast genera and species:

Genus	Species
<i>Arxula</i>	<i>A. adeninivorans</i>
<i>Bullera</i>	<i>B. dendrophila</i>
<i>Cryptococcus</i>	<i>C. albidus</i>
	<i>C. curvatus</i>
	<i>C. macerans</i>
	<i>C. hungaricus</i>
	<i>C. podzolicus</i>
<i>Rhodospiridium</i>	<i>R. paludigenum</i>
	<i>R. sphaerocarpum</i>
	<i>R. toruloides</i>
<i>Rhodotorula</i>	<i>R. araucariae</i>
	<i>R. aurantiaca</i>
	<i>R. glutinis</i>
	<i>R. species</i> (e.g. NCYC 3192, UOFS Y-2042)
<i>Sporidiobolus</i>	<i>S. salmonicolor</i>
<i>Sporobolomyces</i>	<i>S. roseus</i>
	<i>S. sp. "holsaticus"</i>
	<i>S. tsugae</i>
<i>Trichosporon</i>	<i>T. cutaneum</i> var. <i>cutaneum</i>
	<i>T. jirovecii</i>
	<i>T. moniliiforme</i>
	<i>T. species</i> (e.g. NCYC 3210, NCYC 3211)
<i>Yarrowia</i>	<i>Y. lipolytica</i>

- 10 Yeast species referred to in the chart above (and the one below) as "species" correspond to strains obtained from a culture collection, the species of which had not at the time of writing been identified.

Yeast strains innately capable of producing a polypeptide that converts or hydrolyses mixtures of epoxides to optically active (R)-epoxides and/or (S)-vicinal diols include the following exemplary genera and species:

Genus	Species
<i>Arxula</i>	<i>A. terrestris</i>
<i>Bullera</i>	<i>B. dendrophila</i>
<i>Candida</i>	<i>C. magnoliae</i>
	<i>C. parapsilosis</i>
	<i>C. rugosa</i>
	<i>C. tenuis</i>
	<i>C. sp. (new) nearest C. sorbophila</i>
<i>Cryptococcus</i>	<i>C. amyloletus</i>
	<i>C. curvatus</i>
	<i>C. laurentii</i>
	<i>C. luteolus</i>
	<i>C. macerans</i>
<i>Debaryomyces</i>	<i>D. hansenii</i>
<i>Lipomyces</i>	<i>L. species</i>
<i>Pichi</i>	<i>P. finlandica</i>
	<i>P. guillermondii</i>
	<i>P. haplophila</i>
<i>Rhodotorula</i>	<i>R. minuta</i>
	<i>R. mucilaginosa</i>
<i>Sporobolomyces</i>	<i>S. roseus</i>
	<i>S. tsugae</i>
<i>Trichosporon</i>	<i>T. cutaneum var cutaneum</i>
	<i>T. ovoides</i>
<i>Wingea</i>	<i>W. robertsiae</i>

5

The yeast strain can be, for example, one selected from Tables 2 and 3 (see below).

Cultivation in bioreactors of wild-type or recombinant yeast strains expressing the polypeptide or fragment thereof having TDE enantioselective epoxide hydrolase activity (with the purpose of preparing yeasts stocks or for the enantioselective preparative

10

methods of the invention) can be carried out under conditions that provide useful biomass and/or enzyme titer yields. Cultivation can be by batch, fed-batch or continuous culture methods. Useful cultivation conditions are dependent on the yeast strain used. General procedures for establishing useful culturing conditions of yeasts, fungi and bacteria in bioreactors are known to those skilled in the art. The mixture of epoxides can be added directly to the culture. The concentration of the TDE enantiomeric mixture can be at least equal to the solubility of the TDE enantiomeric mixture in the aqueous phase of the reaction mixture. The starting amount of epoxide added to the reaction mixture is not critical. The epoxide can be metered out continuously or in batch mode to the reaction mixture. The relative proportions of (R)- and (S)-epoxide in the mixture of enantiomers of the epoxide shown by the general formula (I) is not critical but it is advantageous for commercial purpose to employ a racemic form of the epoxide shown by the general formula (I). The epoxide can be added in a racemic form or as a mixture of enantiomers in different ratios. The amount of the yeast cells, crude yeast cell extract, or partially purified or isolated polypeptide having TDE enantioselective activity added to the reaction depends on the kinetic parameters of the specific reaction and the amount of epoxide that is to be hydrolysed. In the case of product inhibition, it can be advantageous to remove the formed vicinal diol from the reaction mixture or to maintain the concentration of the vicinal diol at levels that allow reasonable reaction rates. Techniques used to enhance enzyme and biomass yields include the identification of useful (or optimal) carbon sources, nitrogen sources, cultivation time, dilution rates (in the case of continuous culture) and feed rates, carbon starvation, addition of trace elements and growth factors to the culture medium, and addition of inducers for example substrates or substrate analogs of the epoxide hydrolases during cultivation. In the case of recombinant hosts, the conditions under which the promoters function for transcription of the gene encoding the polypeptide with epoxide hydrolase activity are taken into account. At the end of fermentation (culture), biomass and culture medium can be separated by methods known to one skilled in the art, such as filtration or centrifugation.

The processes are generally performed under mild conditions. For example, the reaction can be carried out at a pH from 5 to 10, preferably from 6.5 to 9, and most preferably from 7 to 8.5. The temperature for hydrolysis can be from 0 to 70 °C, preferably from 0 to 50 °C, most preferably from 4 to 40 °C. It is also known that lowering of the temperature of the reaction can enhance enantioselectivity of an enzyme.

The reaction mixture can contain mixtures of water with at least one water-miscible solvents

(e.g., organic water-miscible solvents). Preferably water-miscible solvents are added to the reaction mixture such that epoxide hydrolase activity remains measurable. Water-miscible solvents are preferably organic solvents and can be, for example, acetone, methanol, ethanol, propanol, isopropanol, acetonitrile, dimethylsulfoxide, *N,N*-dimethylformamide, *N*-methylpyrrolidine, and the like.

The reaction mixture can also contain mixtures of water with at least one water-immiscible organic solvent. Examples of water-immiscible solvents that can be used include, for example, toluene, 1,1,2-trichlorotrifluoroethane, methyl *tert*-butyl ether, methyl isobutyl ketone, dibutyl-*o*-phthalate, aliphatic alcohols containing 6 to 9 carbon atoms (for example hexanol, octanol), aliphatic hydrocarbons containing 6 to 16 carbon atoms (for example cyclohexane, *n*-hexane, *n*-octane, *n*-decane, *n*-dodecane, *n*-tetradecane and *n*-hexadecane or mixtures of the aforementioned hydrocarbons), and the like. Thus, the reaction mixture can include water with at least one water-immiscible organic solvent selected from the group consisting of toluene, 1,1,2-trichlorotrifluoroethane, methyl *tert*-butyl ether, methyl isobutyl ketone, dibutyl-*o*-phthalate, aliphatic alcohols containing 6 to 9 carbon atoms, and aliphatic hydrocarbons containing 6 to 16 carbon.

The reaction mixture can also contain surfactants (for example Tween 80), cyclodextrins or phase-transfer catalysts and the like that can increase, selectively or otherwise, the solubility of the epoxide enantiomers in the reaction mixture.

The reaction mixture can also contain a buffer. Buffers are known in the art and include, for example, phosphate buffers, citrate buffers, TRIS buffers, HEPES buffers, and the like.

The production of the YEDH polypeptides, including functional fragments, can be, for example, as recited above in the section on Polypeptides and Polypeptide Fragments. Thus they can be made by production in a natural host cell, production in a recombinant host cell, or synthetic production. Recombinant production can be carried out in host cells of microbial origin. Preferred yeast host cells are selected from, but are not limited to, the genera *Saccharomyces*, *Kluyveromyces*, *Hansenula*, *Pichia*, *Yarrowia*, *Arxula*, and *Candida*. Preferred bacterial host cells include *Escherichia coli*, *Agrobacterium* species, *Bacillus* species and *Streptomyces* species. Preferred filamentous fungal host cells are selected from the group consisting of the genera *Aspergillus*, *Trichoderma* and *Fusarium*. The production of the polypeptide can be, e.g., intra- or extra-cellular production and can be by, e.g., secretion into the culture medium.

In the fermentation reactions, the polypeptides (including functional fragments) can be immobilized on a solid support or free in solution. Procedures for immobilization of the yeast or preparation thereof include, but are not limited to, adsorption; covalent attachment; cross-linked enzyme aggregates; cross-linked enzyme crystals; entrapment in hydrogels; and entrapment into reverse micelles.

The progress of the reaction can be monitored by standard procedures known to one skilled in the art, which include, for example, gas chromatography or high-pressure liquid chromatography on columns containing chiral stationary phases. The vicinal diol formed can be removed from the reaction mixture at one or more stages of the reaction.

The reaction can be stopped when one enantiomer of the epoxide and/or vicinal diol is found to be in excess compared to the other enantiomer of the epoxide and/or vicinal diol. Preferably, the reaction is stopped when one enantiomer of an epoxide of general formula (I) and/or vicinal diol of general formula (II) is found to be in an enantiomeric excess of at least 90%. In a more preferred embodiment of the invention, the reaction is stopped when one enantiomer of an epoxide of general formula (I) and/or vicinal of general formula (II) is found to be in an enantiomeric excess of at least 95%. The reaction can be stopped by the separation (for example centrifugation, membrane filtration, precipitation by solvents, and the like) of the yeast, or preparation thereof, and the reaction mixture or by inactivation (for example by heat treatment or addition of salts and/or organic solvents) of the yeast or polypeptide, or preparation thereof. Thus, the reaction can be stopped by, for example, the separation of the catalytic agent from the reactants and products in the mixture, or by ablation or inhibition of the catalytic activity, by techniques known to one skilled in the art.

The optically active epoxides and/or vicinal diols produced by the reaction can be recovered from the reaction mixture, directly or after removal of the yeast, or preparation thereof. Preferably, the process can include continuously recovering the optically active epoxide and/or vicinal diol produced by the reaction directly from the reaction mixture. Methods of removal of the optically active epoxide and/or vicinal diol produced by the reaction include, for example, extraction with an organic solvent (such as hexane, toluene, diethyl ether, petroleum ether, dichloromethane, chloroform, ethyl acetate and the like), vacuum concentration, crystallisation, distillation, membrane separation, column chromatography and the like.

Thus, the present invention provides an efficient process with economical advantages compared to other chemical and biological methods for the production, in high enantiomeric purity, of optically active epoxides of the general formula (I) and vicinal diols of the general formula (II) in the presence of a yeast strain having epoxide hydrolase activity or a polypeptide that is derived from a yeast strain and has such activity.

YEDH Antibodies

The invention features antibodies that bind to yeast epoxide hydrolase polypeptides or fragments (e.g., antigenic or functional fragments) of such polypeptides. The polypeptides are preferably yeast epoxide polypeptides with enantioselective activity, and in particular those with *meso*-epoxide enantioselective activity (i.e., YEDH), e.g., those with SEQ ID NOs: 1, 2, 3, 4, 5, 6 or 7.. The antibodies preferably bind specifically to yeast epoxide hydrolase polypeptides, i.e., not to epoxide hydrolase polypeptides of species other than yeast species. More preferably, they can bind specifically to yeast epoxide polypeptides with enantioselective activity, and in particular to YEDH polypeptides, e.g., those with SEQ ID NOs: 1, 2, 3, 4, 5, 6 or 7.. They can moreover bind specifically to one or more of polypeptides with SEQ ID NOs: 1, 2, 3, 4, 5, 6, or 7.

Antibodies can be polyclonal or monoclonal antibodies; methods for producing both types of antibody are known in the art. The antibodies can be of any class (e.g., IgM, IgG, IgA, IgD, or IgE). They are preferably IgG antibodies. Moreover, polyclonal antibodies and monoclonal antibodies can be generated in, or generated from B cells from, animals any number of vertebrate (e.g., mammalian) species, e.g., humans, non-human primates (e.g., monkeys, baboons, or chimpanzees), horses, goats, camels, sheep, pigs, bovine animals (e.g., cows, bulls, or oxen), dogs, cats, rabbits, gerbils, hamsters, guinea pigs, rats, mice, birds (such as chickens or turkeys), or fish.

Recombinant antibodies specific for YEDH polypeptides, such as chimeric monoclonal antibodies composed of portions derived from different species and humanized monoclonal antibodies comprising both human and non-human portions, are also encompassed by the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example, using methods described in Robinson et al., International Patent Publication PCT/US86/02269; Akira et al., European Patent Application 184,187; Taniguchi, European Patent Application 171,496; Morrison et

al., European Patent Application 173,494; Neuberger et al., PCT Application WO 86/01533; Cabilly et al., U.S. Patent No. 4,816,567; Cabilly et al., European Patent Application 125,023; Better et al. (1988) Science 240, 1041-43; Liu et al. (1987) J. Immunol. 139, 3521-26; Sun et al. (1987) PNAS 84, 214-18; Nishimura et al. (1987) Canc. Res. 47, 999-1005; Wood et al. (1985) Nature 314, 446-49; Shaw et al. (1988) J. Natl. Cancer Inst. 80, 1553-59; Morrison, (1985) Science 229, 1202-07; Oi et al. (1986) BioTechniques 4, 214; Winter, U.S. Patent No. 5,225,539; Jones et al. (1986) Nature 321, 552-25; Veroeyan et al. (1988) Science 239, 1534; and Beidler et al. (1988) J. Immunol. 141, 4053-60.

Also useful for the invention are antibody fragments and derivatives that contain at least the functional portion of the antigen-binding domain of an antibody that binds to a YEDH polypeptide. Antibody fragments that contain the binding domain of the molecule can be generated by known techniques. Such fragments include, but are not limited to: $F(ab')_2$ fragments that can be produced by pepsin digestion of antibody molecules; Fab fragments that can be generated by reducing the disulfide bridges of $F(ab')_2$ fragments; and Fab fragments that can be generated by treating antibody molecules with papain and a reducing agent. See, e.g., National Institutes of Health, *1 Current Protocols In Immunology*, Coligan et al., ed. 2.8, 2.10 (Wiley Interscience, 1991). Antibody fragments also include Fv fragments, i.e., antibody products in which there are few or no constant region amino acid residues. A single chain Fv fragment (scFv) is a single polypeptide chain that includes both the heavy and light chain variable regions of the antibody from which the scFv is derived. Such fragments can be produced, for example, as described in U.S. Patent No. 4,642,334, which is incorporated herein by reference in its entirety. The antibody can be a "humanized" version of a monoclonal antibody originally generated in a different species.

The above-described antibodies can be used for a variety of purposes including, but not limited to, YEDH polypeptide purification, detection, and quantitative measurement.

The following examples serve to illustrate, not limit, the invention.

EXAMPLES

Example 1. Materials and Methods

Determination of concentrations and enantiomeric excesses

Quantitative determinations of the compounds and determination of enantiomeric excesses in the reactions described in the Examples below were carried out by gas chromatography. Gas chromatography (GLC) was performed on a Hewlett-Packard 6890 gas chromatograph equipped with FID detector and using H₂ as carrier gas. Determination of the enantiomeric excesses for 2-methyl-1,2-epoxyheptane and 2-methyl-1,2-heptanediol was performed by GLC using a fused silica β -DEX 225 cyclodextrin capillary column (Supelco) (30 m length, 25 mm ID and 25 μ m film thickness). The initial temperature of 75°C was maintained for 5.6 minutes, increased at a rate of 8°C per minute to 115°C, and maintained at this temperature for 8.5 minutes. The retention times (min) were as follows: R_t (R)-epoxide = 5.3, R_t (S)-epoxide = 5.6, R_t (S)-diol = 17.9., R_t (R)-diol = 18.4. Determination of the enantiomeric excesses of 2-methyl-3-phenyl-1,2-epoxpropane and 2-methyl-3-phenyl-propanediol was performed by GLC using a fused silica β -DEX 110 cyclodextrin capillary column (Supelco) (30 m length, 25 mm ID and 25 μ m film thickness). The initial temperature of 80°C was maintained for 22 minutes, increased at a rate of 4°C per minute to 160°C, and maintained at this temperature for 1 minute. The retention times (min) were as follows: R_t (S)-epoxide = 31.9, R_t (R)-epoxide = 32.1, R_t (S)-diol = 47.7., R_t (R)-diol = 48.0. Concentrations of epoxides and diols were derived from calibration curves obtained from extractions of the epoxide and diol from buffer in the absence of active cells.

Synthesis of rac 2,2-disubstituted epoxides and vicinal diol standards

(a) Synthesis of 2-methyl-1,2-epoxyheptane and 2-methyl-1,2-heptanediol

rac-2-methyl-1,2-epoxyheptane was synthesised by direct epoxidation of the corresponding alkene with 3-chloroperbenzoic acid in dry CH₂Cl₂: Yield 50%, ¹H-NMR (CDCl₃): δ = 0.8 - 1.0 (t, 3H, J=7 Hz, ω -CH₃), 1.25 - 1.30 (s, 3H, -CH₃), 1.30 - 1.70 (m, 8H, 4 x CH₂), 2.57 - 2.65 (dd, 2H, J = 6.8 and 5.5 Hz, -CH₂O-). 2-Methyl-1,2-heptanediol was synthesized by acid-catalyzed hydrolysis of ($\pm$)-2-methyl-1,2-epoxyheptane in THF-H₂O (Pedragosa-Moreau *et al.*, 1996). The crude product was purified by silica-gel chromatography (CHCl₃/ETOAc 1:1).

(b) Synthesis of 2-methyl-3-phenyl-1,2-epoxpropane and 2-methyl-3-phenyl-propanediol

(i) Synthesis of rac-2-methyl-3-phenyl-1,2-epoxpropane: Methallylbenzene (115.86 g, 0.88 mol) was dissolved in methyl alcohol (460 cm³) containing acetonitrile (82 cm³, 1.58 mol) and anhydrous potassium carbonate (24.53 g, 0.18 mol) in a one litre round bottomed flask

equipped with a magnetic stirrer bar, condenser and pressure-equalising dropping funnel at room temperature. Hydrogen peroxide (35% by mass, 102.2 cm³, 1.05 mol) was then added in a steady stream over about twenty minutes, causing spontaneous boiling of the mixture within thirty minutes of addition commencing. The reaction was left to stir, gradually reaching room temperature over the course of an hour. GC analysis indicated that there was only 55% conversion at this stage. Further acetonitrile (80 cm³, 1.53 mol) and anhydrous potassium carbonate (24.46 g, 0.18 mol) were added to the mixture, and another portion of hydrogen peroxide (35% by mass, 90 cm³, 0.93 mol) was added as before. Conversion had improved to 70-80% typically by this stage. The mixture was placed in a separating funnel, diluted with 400 cm³ of ethyl acetate and the organic component isolated. The aqueous phase was washed with a further 200 cm³ portion of ethyl acetate. The combined organic phases were then concentrated to a yellow heterogeneous suspension, dissolved in 200 cm³ of ethyl acetate, washed twice with 50 cm³ saturated aqueous potassium carbonate, and the isolated organic phase dried with magnesium sulphate and concentrated to a clear yellow oil. Purification by distillation *in vacuo* afforded *rac*-2-methyl-3-phenyl-1,2-epoxypropane (92.88 g, 71%) as a pale yellow oil (bp 73-78 C / 6 mmHg, 95% purity by GC area %). H (200 MHz, CDCl₃) 1.33 (3H, br s), 2.65 (1H, d, *J* 5.0), 2.70 (1H, dd, *J* 4.8 and 0.6), 2.86 (1H, d, *J* 14.2), 2.95 (1H, d, *J* 14.4) and 7.22-7.40 (5H, m).

(ii) *Synthesis of methallylbenzene*: An oven-dried apparatus consisting of a three-necked round bottomed flask equipped with a magnetic stirrer bar, two glass stoppers, a 200 cm³ pressure-equalising dropping funnel and a double-sided spiral condenser was cooled to room temperature under nitrogen atmosphere. The flask was charged with magnesium turnings (15.49 g, 0.64 mol) and anhydrous tetrahydrofuran (75 cm³), and cooled to 0 °C in and ice-water bath. Bromobenzene (8.50 cm³, 80.72 mmol) was then carefully layered over the magnesium turnings, and the magnesium scratched with a glass rod to initiate the reaction. An orange patina formed on the scratched surface, along with the gradual evolution of gas bubbles. Stirring was carefully initiated and the cooling bath removed, although external cooling was often re-applied and removed to moderate the course of this exothermic reaction. After ten minutes, additional bromobenzene (58.57 cm³, 80.72 mmol) in anhydrous tetrahydrofuran (225 cm³) was added dropwise to the magnesium mixture over an hour with intermittent cooling. After a further hour, by which time the reaction was at room temperature, methallylchloride (59.90 cm³, 0.61 mol) in anhydrous tetrahydrofuran (100 cm³) was added dropwise to the solution over an hour. A delayed exotherm occurred about twenty minutes after addition began, that could result in reflux of the mixture if left

unchecked. This was controlled with cooling to about 15 °C during addition. The reaction was allowed to reach room temperature over two hours, affording a dense white suspension. Addition of 200 cm³ of distilled water and mixing for 30 minutes, followed by phase separation, isolation of the organic phase, drying over magnesium sulphate and concentration *in vacuo* gave a light brown oil. The procedure was repeated concurrently in a second experiment, and the combined organic residues distilled. After a brief forerun, methallylbenzene (125.05 g, 78%) was isolated as a clear oil (bp 61-62 C / 10 mmHg, 95% purity by GC area %). H (200 MHz, CDCl₃) 1.72-1.76 (3H, m), 3.39 (2H, br s), 4.78-4.83 (1H, m), 4.84-4.90 (1H, m) and 7.21-7.40 (5H, m).

(iii) *Synthesis of rac-2-methyl-3-phenyl-1,2-propanediol*: A solution of methallylbenzene (20.01 g, 0.15 mol) and *N*-methylmorpholine-*N*-oxide (23.30 g, 0.20 mol) in 7:3 (v/v) acetone:water solution (852 cm³) in a three-necked round bottomed flask was treated with osmium tetroxide (14.1 mg, 55.4 mol), stoppered and stirred at room temperature for seven days. The reaction's progress was monitored by gas chromatography. After this time, all the acetone was stripped off *in vacuo*, and the aqueous phase was extracted with ethyl acetate (2 x 200 cm³). The combined organic phases were dried with magnesium sulphate and concentrated to a brown oil. This was passed through a plug of silica with ethyl acetate as the mobile phase, affording a yellow oil. This was recrystallised from 2% (v/v) ethyl acetate:hexane to yield 2-methyl-3-phenyl-1,2-propanediol (13.53 g, 54%) as colourless needles. H (200 MHz, CDCl₃) 1.17 (3H, s), 2.14 (2H, s), 2.80 (1H, d, *J* 13.2), 2.89 (1H, d, *J* 13.2), 3.45 (1H, d, *J* 11.0), 3.53 (1H, d, *J* 11.0) and 7.20-7.39 (5H, m).

Preparation of frozen yeast cells for screening

Yeast cells were grown at 30°C in 1 L shake-flask cultures containing 200 ml yeast extract/malt extract (YM) mixture (3% yeast extract, 2% malt extract, 1% peptone w/v) supplemented with 1% glucose (w/v). At late stationary phase (48 - 72 h), the cells were harvested by centrifugation (10 000 g, 10 min, 4°C), washed with phosphate buffer (50 mM, pH7.5), pelleted by centrifugation, and frozen in phosphate buffer containing glycerol (20%) at -20°C as 20% (w/v) cell suspensions. The cells were stored for several months without significant loss of activity.

Yeast isolate (strain) screening

Epoxide (10 µl of a 1M stock solution in EtOH) was added to a final concentration of 20 mM

to 500 μ l cell suspension (20% w/v) in phosphate buffer (50 mM, pH 7.5). The reaction mixtures were incubated at 30°C for 2 hours or 5 hours. The reaction mixtures were extracted with EtOAc (300 μ l) and centrifuged. Vicinal diol formation was evaluated by TLC (silica gel Merck 60 F₂₅₄). Compounds were visualized by spraying with vanillin/conc. H₂SO₄ (5g/l). Reaction mixtures that showed substantial diol formation were evaluated for asymmetric hydrolysis of the epoxide by chiral GLC analysis. Some reactions were repeated over longer or shorter times and with more dilute cell suspensions (10%w/v) in order to analyse the reactions at suitable conversions.

General procedure for the hydrolysis of 2,2-disubstituted epoxides

Frozen yeast cells were thawed, washed with phosphate buffer (50 mM, pH 7.5) and resuspended in buffer. Cell suspensions (10 ml, 20% or 50% w/v) were placed in 20 ml glass bottles with screw caps fitted with septa. The substrate (100 or 250 μ l of a 2M (v/v) stock solution in ethanol) was added to final concentrations of 20 mM or 50 mM. The mixtures were agitated on a shaking water bath at 30°C. The course of the bioconversions of epoxides was followed by withdrawing samples (500 μ l) at appropriate time intervals. Samples were extracted with 300 μ l EtOAc. After centrifugation (3000 x g, 2 min), the organic layer was dried over anhydrous MgSO₄ and the products analyzed by chiral GLC.

Determination of the absolute configuration of residual 2,2-disubstituted epoxides and residual diols

(a) 2-methyl-1,2-epoxyheptane and 2-methyl-1,2-heptanediol

Absolute configurations were deduced from reported elution orders of the epoxide and diol enantiomers on cyclodextrin columns (Mischitz *et al.*, 1995).

(b) 2-methyl-3-phenyl-1,2-epoxpropane and 2-methyl-3-phenyl-propanediol

Absolute configurations were deduced from reported elution orders of the epoxide and diol enantiomers on cyclodextrin columns and verified by comparison of the optical rotation of the residual epoxide formed during the biohydrolysis of 2-methyl-3-phenyl-1,2-epoxpropane by yeast strain *Cryptococcus hungaricus* UOFS Y-1346. (S)-2-methyl-3-phenyl-1,2-epoxpropane: $[\alpha]^{22}_D + 5.0$ (c 0.25, MeOH) (Orri *et al.*, 1998). Optical rotation was measured on a Perkin-Elmer 341 polarimeter at 589 nm (Na line) in a 1 dm cuvette.

Cultivation of *Cryptococcus hungaricus* (UOFS Y-1346) in a 10L fed-batch bioreactor

Cultivation was performed at 25 °C in 15 L Braun Biostat C bioreactors (working volume 10 L). An overpressure of 500 mbar was applied to the reactor. Dissolved oxygen was continuously monitored and maintained at 30% saturation by adjustment of the stirrer speed. Airflow rate was controlled at 5.5 L.min⁻¹ by use of a mass flow meter. pH was automatically maintained at 5.5 ± 0.05 by the addition of 25 % (w/v) NH₄OH. Excessive foam formation was avoided by the addition of antifoam (Pluriol P 2000).

A Fernbach shake flask inoculum (10 %, v/v) of *C. hungaricus* (UOFS Y-1346) was transferred into a 15 l Braun Biostat C bioreactor containing 6 l mixture with the following composition (per litre): citric acid, 2.5 g; yeast extract, 7 g; (NH₄)₂SO₄, 58 g; KH₂PO₄, 11.3 g; MgSO₄·7H₂O, 8.2 g; CaCl₂·2H₂O, 0.88 g; NaCl, 0.1 g; H₃PO₄, 13.4; vitamin solution, 1.7 ml; trace element solution, 1 ml; antifoam (Pluriol P-2000), 0.5 ml; and glucose, 20 g. Glucose (60 % m/m) was fed to maintain a residual glucose concentration of 5 g/l after the batch phase. Sugar feed was stopped when the sugar uptake rate decreased. Cultivation was continued for 12 hours after the residual glucose concentration was zero. The biomass was harvested by centrifugation and frozen at -20 °C in phosphate buffer pH 7.5 containing 20 % glycerol until use.

Yeast strains

Yeast strains with screen numbers donated "AB" or "Car" or "Alf" or "Poh" were isolated from soil from specialised ecological niches that were selected based on the inventors' belief that selectivity for specific classes of epoxides in microorganisms can be determined by environmental factors such as terpene-rich environments or highly contaminated soil. "AB" and "Alf" strains were isolated from Cape Mountain fynbos, an ecological environment unique to South Africa, "Car" strains were isolated from soil under pine trees, and "Poh" strains from soil contaminated by high concentrations of cyanide. It seemed likely that microorganisms existing in these contaminated soils would have developed alternative respiratory mechanisms. Nearly all these new isolates displayed activity and selectivity for 2,2-disubstituted epoxides, while only a few of the more than 200 strains from the Yeast Culture Collection that were included in the screening, displayed activity and selectivity for 2,2-disubstituted epoxides. Strains belonging to the species *Cryptococcus curvatus*, *Cryptococcus podzolicus*, and *Cryptococcus laurentii* were all obtained from the environment (as described above) and corresponding strains were not either not available

from the Yeast Culture Collection or did not display the desired selectivity. Furthermore, the strains from the culture collection that were found to be able to produce optically active epoxides and/or diols from 2,2-disubstituted epoxides belonged in most cases to the same species as those isolated from soil from the selected environments. All new isolates that produced optically active epoxides or vicinal diols during hydrolysis of 2,2-disubstituted epoxides were identified by known biochemical characterisation methods, and most of the isolates were also subjected to molecular identification by sequence analysis of the D1/D2 region of the large subunit rDNA. These new isolates were deposited at the Yeast Culture Collection of the University of the Orange Free State (UOFS) and assigned UOFS numbers. Some of the isolates were also deposited at the National Collection of Yeast Cultures (NCYC), Norwich, United Kingdom.

Example II. Cloning and overexpression of wild type yeast epoxide hydrolases in *Yarrowia lipolytica* as production host under the control of different promoters

1. Vectors, Strains and Primers (Table 1)

The following features are common to all the *E. coli*/*Y. lipolytica* auto-cloning integrative vectors used:

- LIP2 terminator
- Zeta regions
- Kanamycin resistance for *E. coli* selection
- mono-copy auto cloning vectors (pINA 1311, pINA 1313, pINA 3313) with a fully functional selection marker gene carry the fully functional *ura3d1* allele from the *URA3* selection marker gene
- multi-copy auto cloning vectors (pINA 1291, pINA 1293, pINA 3293) with a defective selection marker gene (copy number amplification) carry the defective *ura3d4* allele from the *URA3* selection marker gene

Table 1. Vectors, strains and primers

Description				Cloning sites	
Vectors	Promoter	Selection marker	Targeting sequence	Upstream/down stream	Reference/ Origin
pINA1291 (pYLHmA)	hp4d	ura3d4	none	<i>Pml</i> I (blunt) / <i>Bam</i> HI, <i>Kpn</i> I, <i>Avr</i> II	Nicaud <i>et al</i> (2002)
pYL3313 (1313) (pYLTsA)	TEF	ura3d1	none	<i>Xmn</i> I (in pro) / <i>Bam</i> HI, <i>Kpn</i> I, <i>Avr</i> II	This study
Host Strain	Description				Reference/ Origin
<i>Yarrowia lipolytica</i> Polh	<i>MATA</i> , <i>ura3-302</i> , <i>uxpr2-322</i> , <i>axp1-2</i> (deleted for both extracellular proteases and growth on sucrose)				CLIB882
Primers	Sequence			Specifications	
YL-fwd	5'-GGA GTT CTT CGC CCA C-3' (SEQ ID NO:15)			amplification of expression cassette between <i>Not</i> I sites	
YL-rev	5'-GAT CCC CAC CGG AAT TG-3' (SEQ ID NO:16)				
pINA-1	5'- CAT ACA ACC ACA CAC ATC CA-3' (SEQ ID NO:17)			PYLHmA fwd primer	
pINA-2	5'-TAA ATA GCT TAG ATA CCA CAG-3' (SEQ ID NO:18)			pYLTsA/pYLHmA rev primer	
Pina-3	5'-CTC TCT CTC CTT GTC AAC T-3' (SEQ ID NO:19)			pYLTsA fwd primer	

2. Transformants (multi-copy and single-copy)

5

YL Transformants	Gene origin
TEF promoter	Vector: pYL3313 (1313) (pYLTsA)
YL 25 TsA	<i>Rhodotorula araucariae</i> (NCYC 3183)
YL 46 TsA	<i>Rhodospiridium toruloides</i> (UOFS Y-0471)
YL 692 TsA	<i>Rhodospiridium paludigenum</i> (NCYC 3179)
YL 1 TsA	<i>Rhodospiridium toruloides</i> (NCYC 3181)
YL Car 54 TsA	<i>Cryptococcus curvatus</i> (NCYC 3158)
hp4d promoter	Vector: pINA1291=(pYLHmA)
YL 25 HmA	<i>Rhodotorula araucariae</i> (NCYC 3183)
YL 46 HmA	<i>Rhodospiridium toruloides</i> (UOFS Y-0471)
YL 692 HmA	<i>Rhodospiridium paludigenum</i> (NCYC 3179)

3. Vector preparation

pINA1291 (Fig. 20) was obtained from Dr Madzak of Labo de Génétique, INRA, CNRS. This vector was renamed pYLHmA (*Yarrowia Lipolytica* expression vector, with Hp4d promoter, multi-copy integration selection, Absent secretion signal).

pKOV93 (Fig. 21) was prepared by the inventors. This vector was renamed pYLTsA (*Yarrowia Lipolytica* expression vector, with TEF promoter, single-copy integration selection, Absent secretion signal).

To prepare the vectors for ligation with an epoxide hydrolase coding sequence (or other insert to be expressed in *Y. lipolytica*), DNA was digested with *Bam*HI and *Avr*II.

4. Insert preparation

Total RNA was isolated from selected yeast strain cells and messenger RNA (mRNA) was purified from it. The mRNA was used as a template to synthesise complementary DNA (cDNA) using reverse transcriptase. The cDNA was then used as a template for Polymerase Chain Reaction (PCR) using appropriate primers. PCR primers were selected by repeated experimentation using multiple test primers for each yeast strain, the sequences of which were based on previously described epoxide hydrolase sequences from a variety of species. The nucleotide sequences of the forward and reverse primers used to generate cDNA coding sequences from mRNA from six different yeast strains with appropriate restriction enzyme recognition sites at their termini are shown below. Restriction enzyme recognition sequences are underlined and the relevant restriction enzymes are shown in parentheses.

Yeast Strain	Forward primer	Reverse primer
<i>Rhodospiridium toruloides</i> NCYC 3181 #1 <i>Rhodospiridium toruloides</i> UOFS Y-0471 #46 <i>Cryptococcus curvatus</i> NCYC 3158 Car054	GTGGATCCATGGCGACACACA (SEQ ID NO:20) (<i>Bam</i> HI)	GACCTAGGCTACTTCTCCCA CA (SEQ ID NO:21) (<i>Bln</i> I)
<i>Rhodotorula araucariae</i> NCYC 3183 #25	GATTAATGATCAATGAGCGAGCA (SEQ ID NO:22) (<i>Bcl</i> II)	GACCTAGGTCACGACGACA G (SEQ ID NO:23) (<i>Bln</i> I)
<i>Rhodospiridium paludigenum</i> NCYC 3179 #692	GTGGATCCATGGCTGCCCA (SEQ ID NO :24) (<i>Bam</i> HI)	GAGCTAGCTCAGGCCTGG (SEQ ID NO:25) (<i>Nhe</i> I)
<i>Debaromyces hansenii</i> NCYC 3167 (#113)	GTGGATCCATGATGCAAGG (SEQ ID NO:26) (<i>Bam</i> HI)	GACCTAGGCTAAGGATATT (SEQ ID NO:27) (<i>Bln</i> I)

Each PCR reaction contained 200 μ M dNTPs, 250 nM of each primer, 2 mM of $MgCl_2$, cDNA and 2.5 U of Taq polymerase in a 50 μ l reaction volume. The PCR profile used was: 95°C for 5 minutes, followed by 30 cycles of: 95°C – 1 min, 50°C – 1 min, 72°C – 2 min, then a final extension of 72°C for 10 minutes. The PCR product were purified and digested with the restriction enzymes whose recognition sites are engineered at the end of the primers. The cDNA fragment was cloned into a vector and sequenced for confirmation.

Coding sequences to be inserted in either pYLHmA or pYLTsA were prepared with *Bam*HI and *Avr*II at their termini. The above PCR primers were designed with these restriction sites, unless the sites were also present in the gene to be inserted. If this occurred, appropriate compatible restriction enzymes were selected. PCR template DNA was either the insert cloned into a different vector, or cDNA synthesized from the original host organism. PCR reactions consisted of 200 μ M dNTP's, 250 nM each primer, 1X Taq polymerase buffer, and 2.5 units Taq polymerase per 100 μ l reaction. The amplification programme used was: 95°C for 5 minutes, followed by 30 cycles of 95°C for 1 minute, 50°C for 1 minute, followed by a final extension at 72°C for 2 minutes, followed by 72°C for 10 minutes.

PCR products were purified and digested with the relevant restriction enzymes. The digested DNA was subsequently repurified and was ready for ligation into the prepared vector.

5. Preparation of pYLHmA or pYLTsA constructs

Vector and insert were ligated at pmol end ratios of 3:1 – 10:1 (insert:vector), using

commercial T4 DNA Ligase. Ligations were electroporated into any laboratory strain of *Escherichia coli*, using the Bio-Rad GenePulser, or equivalent electroporator. Transformants were selected on LM media (10 g/l yeast extract, 10 g/l tryptone, 5 g/l NaCl), supplemented with kanamycin (50 µg/ml). Transformants were selected based on restriction enzyme digests of purified plasmid DNA.

6. *Yarrowia lipolytica* transformation

6.1.1. Preparation of DNA – method 1

Digestion of the pINA-series of plasmids with *NotI* resulted in the release of a bacterial DNA-free expression cassette, containing the *ura3d4* (pYLHmA) or the *ura3d1* (pYLTsA) marker gene and the promoter-gene-terminator.

Scaled-up quantities of each plasmid were isolated. *NotI* was used to restrict the plasmid DNA, and the digested DNA was run on an agarose gel. *NotI* digests resulted in generation of the bacterial fragment of the plasmid as a band at 2210 bp, and the expression cassette as a band of 2760 bp + size of insert (pYLHmA) or 2596 bp + size of insert (pYLTsA). The expression cassette fragments were excised from the gel and purified from the agarose. The purified fragment was used for transformation of *Y. lipolytica* Po1h.

6.1.2. Preparation of DNA – method 2

Primers YL-Fwd and YL-Rev (Table 1) were used to amplify the expression cassette. PCR reactions consisted of 200 µM dNTP's, 250 pmol each primer, 1X Taq polymerase buffer and 2.5 units Taq polymerase per 100 µl reaction. The amplification programme used was 95°C for 5 minutes, 30 cycles of 95°C for 1 minute, 50°C for 1 minute, and 72°C for 3 ½ minutes; followed by a final extension at 72°C for 10 minutes. The PCR product was purified from the PCR reaction mix and used for transformation of *Y. lipolytica* Po1h.

6.1.3. Preparation of carrier DNA

DNA from salmon testes was made up as a 10 mg/ml stock in TE (10 mM Tris-HCl, pH 8.0, 1 mM EDTA) and sonicated to result in fragments that ranged from approximately 15 kb to 100 bp, with most fragments in a range of 6 to 10 kb. The DNA was denatured by boiling. Aliquots were stored at -20°C.

6.1.4. Transformation of *Yarrowia lipolytica* with pYLHmA or pYLTsA

An adaptation of the method of Xuan *et al* (1988) was used for the transformation of *Y. lipolytica* Po1h. The yeast was inoculated into 50 ml YPD (10 g/l yeast extract, 20 g/l peptone, 20 g/l glucose). The culture was incubated at 30°C, 220 rpm until cell densities of 8×10^7 - 2×10^8 cells/ml were reached. The entire culture was harvested, the pellet
5 resuspended in 10 ml TE and reharvested. 1 ml TE + 0.1 M LiOAc was used to resuspend the pellet and the culture was incubated at 28°C in a ProBlot Jr (Labnet) hybridisation oven, set at 4 rpm (or similar incubator) for 1 hour. Transformation mixes were set up with 0.5 – 2 µg of transforming DNA + 5 µg of carrier DNA with 100 µl of treated cells.

Each mix was set up in a 1.5 ml microfuge tube, and incubated in a 28°C heating block for 30 minutes. 7 volumes of PEG reagent (40% PEG 4,000, 0.1 M LiOAc, 10 mM Tris, 1 mM EDTA, pH 7.5, filter-sterilised) were added to each, mixed carefully and incubated at 28°C for a further 1 hour. The tubes were transferred to a 37°C heating block for 15 minutes, and then the cells were pelleted by centrifugation for 1 minute at 13,000 rpm. The cell pellets
15 were carefully resuspended in 100 µl dH₂O. The transformations were plated on *Y. lipolytica* selective plates (17 g/l Difco yeast nitrogen base without amino acids and without (NH₄)₂SO₄, 20 g/l glucose, 4 g/l NH₄Cl, 2 g/l casamino acids, 300 mg/l leucine) and incubated at 28°C.

Colonies which appeared on the selective plates after 3 – 7 days were transferred onto fresh plates and regrown.

6.1.5. Confirmation of integration of pYLHmA or pYLTsA

Colonies that grew on the newly-streaked selective plates were inoculated into 5 ml of YPD
25 medium and grown at 30°C, 200 rpm for 24-48 hours. A small-scale genomic DNA isolation was performed.

PCR was performed using this genomic DNA as template, with either pINA-1 and pINA-2 as primers (transformants with pYLHmA), or pINA-3 and pINA-2 (pYLTsA) (Table 1). Each
30 PCR reaction contained 200 µM dNTPs, 250 nM of each primer, 2 mM of MgCl₂, genomic DNA and 2.5 U/50µl of Taq polymerase. The PCR profile was as described above in this example. These primer sets gave products the size of the inserted genes.

Example III. Selection of yeasts able to produce optically active 2-methyl-1,2-epoxyheptane and 2-methyl-2-heptanediol from (±)-2-methyl-1,2-epoxyheptane
35

Yeasts were cultivated, harvested and frozen as described above. 2,2-disubstituted epoxide 2-methyl-1,2-epoxyheptane was added and the screening was performed as described above. Strains with the highest activities as judged by TLC from diol formation were subjected to chiral GC analysis as described above. The strains with E-values > 2 are depicted as Samples 1-114 (Table 2). E-values were calculated from the following formulas:

$$E = \frac{\ln [(1 - \xi)(1 - ee_s)]}{\ln [(1 - \xi)(1 + ee_s)]} \quad \text{where} \quad \begin{array}{l} \xi = \text{degree of conversion} \\ ee_s = \text{substrate enantiomeric excess} \end{array} \quad (1)$$

$$E = \frac{\ln [1 - \xi(1 + ee_p)]}{\ln [1 - \xi(1 - ee_p)]} \quad \text{where} \quad \begin{array}{l} \xi = \text{degree of conversion} \\ ee_p = \text{product enantiomeric excess} \end{array} \quad (2)$$

$$E = \frac{\ln \left[\frac{ee_p(1 - ee_s)}{(ee_p + ee_s)} \right]}{\ln \left[\frac{ee_p(1 + ee_s)}{(ee_p + ee_s)} \right]} \quad \text{where} \quad \begin{array}{l} ee_s = \text{substrate enantiomeric excess} \\ ee_p = \text{product enantiomeric excess} \end{array} \quad (3)$$

Enantiomeric excess (ee) (%) = $\{([R] - [S]) / ([R] + [S])\} \times 100\%$, where [R] and [S] represent the concentrations of the R and S enantiomers of the TDE substrate or the DVD product, depending on whether the ee of the substrate or the product is to be calculated.

Notes:

The conversion at appropriate time intervals and ee's of the substrate and product was used to determine E-values calculated from ee_s and conversion (Equation 1), ee_p and conversion (Equation 2), and ee_s and ee_p (Equation 3) respectively for strains (114) that displayed the most promising enantioselectivities (Table 2). If the degree of conversion can be accurately determined, E-values calculated from all three equations should be the same, provided that the reaction is irreversible and regiospecific (Pedragosa- Moreau *et al.* 1996). In this case, both the epoxide and diol could be extracted very efficiently, and the degree of conversion could be determined with high accuracy. If the reaction is not regioselective, E-values are not applicable, since E-values calculated from ee_s and conversion and from ee_p and conversion will differ substantially and highly erroneous results will be obtained. If each of the two antipodes of the epoxide is attacked following a different regioselectivity, the ee of the diol will be high, and E-values based on ee_p and conversion will be higher than those obtained from ee_s and conversion and from ee_s and ee_p . Strains displaying this type of regioselectivity can then be used for the synthesis of diol in high enantiomeric purity, which is difficult to obtain in high yields from enantioselective but

regiospecific reactions. On the other hand, if a catalyst is enantioselective but not regioselective, the ee of the remaining epoxide will be high while the ee of the diol formed will be low, and E-values based on ee_s and conversion will be higher than those obtained from ee_p and conversion and from ee_s and ee_p. Strains displaying this type of regioselectivity can then be used for the synthesis of epoxide in high enantiomeric purity. Comparison of E-values calculated from the different equations can thus be used as a qualitative tool to analyse the enantioselectivity and regioselectivity of the reaction and to make appropriate choices of biocatalysts for the synthesis of the desired epoxide or diol enantiomers in high yields and optical purity.

Table 2. Yeast strains that hydrolyse 2-methyl-1,2-epoxyheptane enantioselectively (E > 2)^a

Samp no.	Screen no	Yeast species	Culture Collec- tion Nr	Reaction		Remaining Epoxide		Formed Diol		Selectivity		
				Time (min)	Conv (%)	E.e. (%)	Abs conf	E.e. (%)	Abs Conf	E ^b	E ^c	E ^d
1	269	<i>Arxula adenivorans</i>	NCYC 3147	90	3.2	0.7	S	82.5	R	1.6	10.7	10.5
2	693	<i>Arxula terrestris</i>	NCYC 3148	180	17.0	13.3	R	58.0	S	5.4	4.2	4.3
3	43	<i>Bullera dendrophila</i>	NCYC 3152	180	37.5	46.7	S	82.6	R	12.7	17.1	16.6
4	669	<i>Candida magnoliae</i>	NCYC 3154	180	17.9	11.7	R	43.6	S	3.7	2.8	2.9
5	677	<i>Candida magnoliae</i>	UOFS Y-0799	180	28.8	17.4	R	37.1	S	3.0	2.5	2.6
6	751	<i>Candida magnoliae</i>	UOFS Y-1040	60	18.6	14.4	R	41.3	S	5.0	2.6	2.8
7	678	<i>Candida magnoliae</i>	UOFS Y-1297	180	47.4	28.2	R	31.6	S	2.5	2.5	2.5
8	230	<i>Cryptococcus albidus</i>	NCYC 3156	180	14.7	9.3	S	68.7	R	3.7	6.0	5.9
9	Jen 17	<i>Cryptococcus albidus</i>	UOFS Y-0223	90	5.2	3.9	S	74.5	R	6.2	7.1	7.1
10	Jen 03	<i>Cryptococcus albidus</i>	UOFS Y-0821	90	4.7	2.9	S	30.5	R	4.0	1.9	1.9
11	375	<i>Cryptococcus amylo lentus</i>	NCYC 3157	90	31.9	43.5	R	91.8	S	42.0	35.8	36.0
12	Car 054	<i>Cryptococcus curvatus</i>	NCYC 3158	10	46.9	54.8	S	48.2	S	7.3	4.3	4.8
13	379	<i>Cryptococcus hungaricus</i>	NCYC 3159	90	33.7	32.1	S	55.7	R	6.0	4.6	4.8
14	Jen	<i>Cryptococcus</i>	NCYC	90	2.6	0.8	R	65.3	S	1.9	4.9	4.8

Samp no.	Screen no	Yeast species	Culture Collec- tion Nr	Reaction		Remaining Epoxide		Formed Diol		Selectivity		
				Time (min)	Conv (%)	E.e. (%)	Abs conf	E.e. (%)	Abs Conf	E ^b	E ^c	E ^d
	12	<i>laurentii</i>	3160									
15	AB 24	<i>Cryptococcus laurentii</i>	NCYC 3161	180	71.6	48.0	R	26.4	S	2.2	3.1	2.6
16	Alf 12	<i>Cryptococcus laurentii</i>	UOFS Y-0509	180	34.9	22.0	R	37.3	S	0.0	2.6	2.7
17	Alf 03	<i>Cryptococcus laurentii</i>	UOFS Y-0514	180	56.8	38.3	R	33.7	S	2.6	3.0	2.9
18	AB 25	<i>Cryptococcus laurentii</i>	UOFS Y-1884	180	62.1	43.3	R	30.3	S	2.5	3.0	3.0
19	AB 26	<i>Cryptococcus laurentii</i>	UOFS Y-1885	180	69.0	51.9	R	27.2	S	2.5	3.0	2.8
20	AB 27	<i>Cryptococcus laurentii</i>	UOFS Y-1886	180	42.7	26.4	R	37.6	S	2.7	2.9	2.8
21	AB 32	<i>Cryptococcus laurentii</i>	UOFS Y-1887	180	59.7	41.9	R	30.9	S	2.6	2.9	2.8
22	AB 33	<i>Cryptococcus laurentii</i>	UOFS Y-1888	180	53.6	36.9	R	33.9	S	2.7	2.9	2.8
23	AB 35	<i>Cryptococcus laurentii</i>	UOFS Y-1892	180	44.8	35.2	R	46.4	S	3.5	3.9	3.8
24	Jen 09	<i>Cryptococcus laurentii</i> var. <i>laurentii</i>	UOFS Y-1349	90	1.2	0.5	R	50.6	S	2.4	3.1	3.1
25	AB 58	<i>Cryptococcus podzolicus</i>	NCYC 3164	180	38.7	45.4	S	94.4	R	9.4	64.2	54.7
26	AB 53	<i>Cryptococcus podzolicus</i>	NCYC 3165	180	10.1	6.7	S	84.4	R	4.3	12.9	12.6
27	AB 40	<i>Cryptococcus podzolicus</i>	UOFS Y-1881	180	27.7	33.4	S	93.9	R	20.3	45.3	44.1
28	AB 49	<i>Cryptococcus podzolicus</i>	UOFS Y-1882	180	43.0	52.2	S	94.3	R	9.1	72.2	57.0
29	AB 50	<i>Cryptococcus podzolicus</i>	UOFS Y-1883	180	50.0	85.5	S	92.7	R	34.8	88.5	72.1
30	AB 28	<i>Cryptococcus podzolicus</i>	UOFS Y-1889	180	34.7	49.7	S	93.7	R	49.2	50.6	50.5
31	AB 34	<i>Cryptococcus podzolicus</i>	UOFS Y-1890	180	42.6	66.7	S	90.1	R	37.6	38.4	38.4
32	AB 36	<i>Cryptococcus podzolicus</i>	UOFS Y-1893	180	42.2	58.4	S	93.7	R	16.1	62.6	55.1
33	AB 52	<i>Cryptococcus podzolicus</i>	UOFS Y-1895	180	39.3	41.4	S	94.4	R	6.8	64.7	52.0
34	AB 37	<i>Cryptococcus podzolicus</i>	UOFS Y-1896	180	52.0	70.2	S	89.7	R	9.6	79.1	38.6
35	AB 29	<i>Cryptococcus podzolicus</i>	UOFS Y-1897	180	38.9	57.3	S	94.0	R	34.6	59.9	58.2
36	AB 41	<i>Cryptococcus podzolicus</i>	UOFS Y-1899	180	25.3	27.3	S	93.5	R	12.1	40.7	39.0
37	AB	<i>Cryptococcus</i>	UOFS	180	43.2	70.9	S	93.9	R	61.9	68.1	67.7

Samp no.	Screen no	Yeast species	Culture Collec- tion Nr	Reaction		Remaining Epoxide		Formed Diol		Selectivity		
				Time (min)	Conv (%)	E.e. (%)	Abs conf	E.e. (%)	Abs Conf	E ^b	E ^c	E ^d
	30	<i>podzolicus</i>	Y-1904									
38	AB 45	<i>Cryptococcus podzolicus</i>	UOFS Y-1906	180	42.6	45.9	S	92.6	R	6.6	53.6	40.9
39	AB 46	<i>Cryptococcus podzolicus</i>	UOFS Y-1907	180	27.8	22.5	S	90.4	R	4.7	27.8	24.6
40	AB 47	<i>Cryptococcus podzolicus</i>	UOFS Y-1908	180	23.2	19.5	S	89.9	R	5.6	24.4	22.6
41	AB 48	<i>Cryptococcus podzolicus</i>	UOFS Y-1910	180	28.1	24.4	S	88.7	R	7.7	22.0	19.7
42	AB 39	<i>Cryptococcus podzolicus</i>	UOFS Y-1912	180	50.4	70.7	S	92.4	R	11.6	90.1	53.7
43	AB 56	<i>Cryptococcus podzolicus</i>	UOFS Y-1913	180	42.7	36.5	S	92.4	R	4.1	52.5	36.3
44	AB 57	<i>Cryptococcus podzolicus</i>	UOFS Y-1914	180	46.6	57.6	S	92.8	R	8.6	66.7	47.8
45	520	<i>Pichia finlandica</i>	NCYC 3173	180	70.6	79.6	R	30.8	S	4.4	3.8	4.1
46	676	<i>Pichia haplophila</i>	NCYC 3176	180	19.1	22.7	R	98.0	S	64.0	127.2	126. 6
47	673	<i>Pichia haplophila</i>	NCYC 3177	60	37.2	40.7	R	53.7	S	7.9	4.5	4.9
48	28	<i>Pichia haplophila</i>	UOFS Y-2136	60	29.9	31.1	R	56.3	S	8.7	4.5	4.8
49	692	<i>Rhodospiridium paludigenum</i>	NCYC 3179	180	72.9	100.0	S	36.5	R	17.2	8.4	16.8
50	Alf 01	<i>Rhodospiridium toruloides</i>	NCYC 3181	10	98.0	100.0	S	23.7	R	4.1	6.5	11.3
51	Car 118	<i>Rhodospiridium toruloides</i>	NCYC 3182	20	23.5	27.6	S	63.3	R	23.7	5.4	5.8
52	671	<i>Rhodospiridium toruloides</i>	UOFS Y-0472	180	52.9	33.2	S	31.4	R	2.5	2.6	2.6
53	Alf 02	<i>Rhodospiridium toruloides</i>	UOFS Y-0518	20	46.9	51.0	S	57.4	R	6.0	6.0	6.0
54	Car 003	<i>Rhodospiridium toruloides</i>	UOFS Y-2222	20	31.2	38.0	S	59.5	R	16.3	5.1	5.6
55	Car 006	<i>Rhodospiridium toruloides</i>	UOFS Y-2223	20	26.1	32.7	S	61.2	R	35.7	5.1	5.7
56	Car 020	<i>Rhodospiridium toruloides</i>	UOFS Y-2226	20	41.6	44.6	S	57.1	R	6.7	5.4	5.6
57	Car 038	<i>Rhodospiridium toruloides</i>	UOFS Y-2228	20	23.5	28.4	S	63.6	R	34.1	5.4	5.9
58	Car 052	<i>Rhodospiridium toruloides</i>	UOFS Y-2230	20	45.9	55.9	S	53.5	R	8.4	5.1	5.6
59	Car 059	<i>Rhodospiridium toruloides</i>	UOFS Y-2231	20	37.7	39.3	S	58.1	R	6.8	5.3	5.5
60	Car 067	<i>Rhodospiridium toruloides</i>	UOFS Y-2236	20	23.3	29.4	S	64.1	R	83.0	5.5	6.1

Samp no.	Screen no	Yeast species	Culture Collec- tion Nr	Reaction		Remaining Epoxide		Formed Diol		Selectivity		
				Time (min)	Conv (%)	E.e. (%)	Abs conf	E.e. (%)	Abs Conf	E ^b	E ^c	E ^d
61	Car 070	<i>Rhodospiridium toruloides</i>	UOFS Y-2237	60	66.8	100.0	S	37.5	R	25.1	4.6	17.3
62	Car 076	<i>Rhodospiridium toruloides</i>	UOFS Y-2238	60	81.8	100.0	S	18.3	R	10.8	3.1	9.4
63	Car 077	<i>Rhodospiridium toruloides</i>	UOFS Y-2239	60	83.5	100.0	S	16.1	R	9.9	2.9	8.7
64	Car 078	<i>Rhodospiridium toruloides</i>	UOFS Y-2240	20	27.1	28.6	S	63.2	R	10.2	5.6	5.8
65	Car 092	<i>Rhodospiridium toruloides</i>	UOFS Y-2241	60	83.9	100.0	S	15.8	R	9.7	2.9	8.6
66	Car 093	<i>Rhodospiridium toruloides</i>	UOFS Y-2242	60	81.9	100.0	S	18.1	R	10.7	3.1	9.4
67	Car 094	<i>Rhodospiridium toruloides</i>	UOFS Y-2243	20	22.5	27.7	S	63.0	R	56.1	5.3	5.7
68	Car 100	<i>Rhodospiridium toruloides</i>	UOFS Y-2245	60	66.7	100.0	S	37.1	R	25.4	4.5	17.1
69	Car 103	<i>Rhodospiridium toruloides</i>	UOFS Y-2246	60	66.5	100.0	S	37.2	R	25.7	4.5	17.2
70	Car 108	<i>Rhodospiridium toruloides</i>	UOFS Y-2247	60	82.6	100.0	S	17.7	R	10.4	3.2	9.3
71	Car 120	<i>Rhodospiridium toruloides</i>	UOFS Y-2249	60	82.5	100.0	S	17.5	R	10.4	3.1	9.2
72	Car 121	<i>Rhodospiridium toruloides</i>	UOFS Y-2250	60	80.9	100.0	S	19.6	R	11.3	3.2	9.9
73	Car 126	<i>Rhodospiridium toruloides</i>	UOFS Y-2251	20	29.3	38.0	S	58.6	R	33.9	4.8	5.5
74	Car 131	<i>Rhodospiridium toruloides</i>	UOFS Y-2252	60	66.0	100.0	S	37.3	R	26.7	4.4	17.2
75	Car 134	<i>Rhodospiridium toruloides</i>	UOFS Y-2253	60	81.9	100.0	S	18.1	R	10.7	3.1	9.4
76	Car 142	<i>Rhodospiridium toruloides</i>	UOFS Y-2255	60	71.7	90.0	S	29.3	R	5.8	3.7	4.9
77	Car 200	<i>Rhodospiridium toruloides</i>	UOFS Y-2256	10	34.8	37.0	S	53.2	R	7.9	4.3	4.6
78	Car 204	<i>Rhodospiridium toruloides</i>	UOFS Y-2257	60	83.9	100.0	S	15.8	R	9.7	2.9	8.6
79	Car 205	<i>Rhodospiridium toruloides</i>	UOFS Y-2258	60	63.8	100.0	S	40.0	R	31.5	4.6	18.7
80	Car 209	<i>Rhodospiridium toruloides</i>	UOFS Y-2260	20	14.3	15.5	S	68.1	R	31.2	5.9	6.1
81	Car 210	<i>Rhodospiridium toruloides</i>	UOFS Y-2261	60	80.7	100.0	S	19.1	R	11.4	3.1	9.7
82	46	<i>Rhodospiridium toruloides</i>	UOFS Y-0471	20	11.6	11.0	S	74.2	R	12.3	7.4	7.5
83	25	<i>Rhodotorula araucariae</i>	NCYC 3183	180	65.2	57.5	S	33.5	R	3.2	3.6	3.4
84	EP	<i>Rhodotorula</i>	NCYC	180	54.7	46.0	S	51.9	R	3.4	5.8	4.9

Samp no.	Screen no	Yeast species	Culture Collec- tion Nr	Reaction		Remaining Epoxide		Formed Diol		Selectivity		
				Time (min)	Conv (%)	E.e. (%)	Abs conf	E.e. (%)	Abs Conf	E ^b	E ^c	E ^d
	230	<i>aurantiaca</i>	3185									
85	50	<i>Rhodotorula glutinis</i>	NCYC 3186	20	62.2	87.5	S	46.1	R	8.9	5.9	7.2
86	680	<i>Rhodotorula glutinis</i>	UOFS Y-0459	20	57.3	75.2	S	51.5	R	7.7	6.2	6.8
87	713	<i>Rhodotorula glutinis</i>	UOFS Y-0489	60	62.5	100.0	S	37.7	R	35.3	4.0	17.5
88	Alf 06	<i>Rhodotorula glutinis</i>	UOFS Y-0513	20	22.8	28.4	S	64.0	R	63.9	5.5	6.0
89	Car 022	<i>Rhodotorula glutinis</i>	UOFS Y-2227	60	75.9	100.0	S	26.3	R	14.5	3.9	12.3
90	Car 060	<i>Rhodotorula glutinis</i>	UOFS Y-2232	20	33.9	38.6	S	59.3	R	10.2	5.2	5.6
91	Car 061	<i>Rhodotorula glutinis</i>	UOFS Y-2233	60	74.8	100.0	S	27.8	R	15.5	4.0	12.9
92	Car 062	<i>Rhodotorula glutinis</i>	UOFS Y-2234	20	27.3	31.3	S	61.7	R	14.8	5.3	5.7
93	Car 066	<i>Rhodotorula glutinis</i>	UOFS Y-2235	60	77.3	100.0	S	24.1	R	13.5	3.6	11.5
94	Car 075	<i>Rhodotorula glutinis</i>	UOFS Y-2265	20	42.8	45.3	S	57.0	R	6.3	5.5	5.6
95	714	<i>Rhodotorula minuta</i>	NCYC 3187	20	33.3	24.0	R	37.9	S	3.6	2.7	2.8
96	712	<i>Rhodotorula minuta</i>	UOFS Y-0835	60	46.9	52.7	R	48.4	S	6.6	4.3	4.7
97	686	<i>Rhodotorula minuta</i> var. <i>minuta</i>	NCYC 3188	60	30.1	25.8	R	50.5	S	5.1	3.7	3.9
98	158	<i>Rhodotorula</i> sp. "minuta/mucilag inosa"	NCYC 3194	180	40.1	21.5	R	31.5	S	2.4	2.3	2.3
99	690	<i>Rhodotorula</i> sp. "nearest minuta"	UOFS Y-0125	180	49.3	29.5	R	28.2	S	2.4	2.3	2.3
100	172	<i>Rhodotorula</i> sp.	NCYC 3192	180	54.9	83.0	S	70.9	R	13.4	16.0	14.9
101	165	<i>Rhodotorula</i> sp.	NCYC 3193	180	16.9	13.3	S	69.6	R	5.5	6.4	6.4
102	24	<i>Rhodotorula</i> sp.	UOFS Y-2042	180	18.3	17.4	S	83.2	R	9.3	13.1	12.9
103	293	<i>Sporidiobolus salmonicolor</i>	NCYC 3195	90	9.4	8.1	S	61.3	R	8.8	4.4	4.5
104	42	<i>Sporidiobolus salmonicolor</i>	NCYC 3196	90	13.2	13.0	S	60.2	R	14.3	4.4	4.6
105	285	<i>Sporobolomyces roseus</i>	NCYC 3197	90	44.0	62.0	S	52.4	R	15.9	4.7	5.9
106	696	<i>Sporobolomyces</i>	NCYC	180	46.3	39.1	S	45.2	R	3.8	3.8	3.8

Samp no.	Screen no	Yeast species	Culture Collec- tion Nr	Reaction		Remaining Epoxide		Formed Diol		Selectivity		
				Time (min)	Conv (%)	E.e. (%)	Abs conf	E.e. (%)	Abs Conf	E ^b	E ^c	E ^d
		<i>sp. "holsaticus"</i>	3198									
107	283	<i>Sporobolomyces tsugae</i>	NCYC 3199	90	8.3	6.5	S	18.7	S	6.4	1.5	1.6
108	20	<i>Trichosporon cutaneum</i> var <i>cutaneum</i>	NCYC 3201	180	24.1	15.9	R	61.7	S	3.5	5.1	4.9
109	14	<i>Trichosporon mucoides</i>	NCYC 3205	180	17.0	8.3	R	3.3	S	2.6	1.1	1.1
110	19	<i>Trichosporon ovoides</i>	NCYC 3207	180	40.5	27.8	R	41.2	S	3.1	3.1	3.1
111	225	<i>Trichosporon sp.</i>	NCYC 3211	180	36.6	21.1	S	37.4	R	2.6	2.7	2.7
112	39	<i>Wingea robertsiae</i>	NCYC 3228	180	9.3	6.3	R	45.3	S	4.4	2.8	2.8
113	711	<i>Yarrowia lipolytica</i>	NCYC 3229	180	8.6	7.5	S	73.5	R	9.8	7.0	7.1
114	Jen 48	<i>Yarrowia lipolytica</i>	UOFS Y-1700	90	6.5	5.1	S	98.1	R	7.1	109	107

^a Reaction conditions: 20 mM epoxide, 20 % cells [(w/v), wet weight] in phosphate buffer (50 mM, pH 7.5)

^b E calculated from equation 1

5 ^c E calculated from equation 2

^d E calculated from equation 3

10 All the yeast strains corresponding to sample 1-114 (Table 2) are kept and maintained at the University of the Orange Free State (UOFS), Department of Microbial, Biochemical and Food Biotechnology, Faculty of Natural and Agricultural Sciences, P.O. Box 339, Bloemfontein 9300, South Africa (Tel +27 51 401 2396, Fax + 27 51 444 3219) and are readily identified by the yeast species and culture collection number as indicated. Representative examples of strains belonging to the different species have been deposited under the Budapest Treaty at National Collection of Yeast Cultures (NCYC), Institute of Food Research Norwich Research Park Colney, Norwich NR4 7UA, U.K. (Tel: +44-15 1603-255274 Fax: +44-(0)1603-458414 Email: ncyc@bbsrc.ac.uk) and are readily identified by the yeast species and culture collection accession number as indicated. The samples deposited with the NCYC are taken from the same deposit maintained by the South African Council for Scientific and Industrial Research (CSIR) since prior to the filing date of this application. The deposits will be maintained without restriction in the NCYC

depository for a period of 30 years, or 5 years after the most recent request, or for the effective life of the patent, whichever is longer, and will be replaced if the deposit becomes non-viable during that period. Samples of the yeast strains not deposited at NCYC will be made available upon request on the same basis and conditions of the Budapest Treaty.

5

Example IV. Selection of yeasts that are able to produce optically active 2-methyl-3-phenyl-1,2-epoxypropane and 2-methyl-3-phenyl-1,2-propanediol from (±)-2-methyl-3-phenyl-1,2-epoxypropane

10 Yeasts were cultivated, harvested and frozen as described above. The 2,2-disubstituted epoxide 2-methyl-3-phenyl-1,2-epoxypropane was added and the screening was performed as described above. Strains with the highest activities as judged by TLC from diol formation were subjected to chiral GC analysis as described above. The strains that were able to produce optically active 2-methyl-3-phenyl-1,2-epoxypropane and 2-methyl-3-phenyl-1,2-propanediol from the racemic epoxide are listed as samples 115-210 in Table 3.

15

Table 3. Yeast strains that hydrolyse 2-methyl-3-phenyl-1,2-epoxypropane enantioselectively

Sample No	Screen no	Yeast species	Culture Collection no.	Epoxide ee	Diol ee	E ^a	Abs.conf.	
				(%)	(%)		Epox.	Diol
115	43	<i>Bullera dendrophila</i>	NCYC 3152	32.2	15.7	1.8	R	S
116	Jen-26	<i>Bullera dendrophila</i>	NCYC 3208	21.1	20.2	1.8	R	S
117	708	<i>Candida rugosa</i>	NCYC 3155	3.4	26.1	1.8	R	S
118	POH-29	<i>Candida</i> sp. (new) (<i>C. sorbophila</i>)	NCYC 3217	6.5	78.5	8.9	R	S
119	Jen-2	<i>Cryptococcus albidus</i>	NCYC 3156	26.5	93.8	40.2	S	R
120	Jen-17	<i>Cryptococcus albidus</i>	UOFS Y-0223	21.5	58.6	4.7	S	R
121	Jen-3	<i>Cryptococcus albidus</i>	UOFS Y-0821	100	63.0	38.8	S	R
122	Jen-23	<i>Cryptococcus amyloletus</i>	NCYC 3157	42.2	65.8	7.3	R	S
123	Car-14	<i>Cryptococcus curvatus</i>	UOFS Y-2225	8.5	34.9	2.2	R	S
124	Jen-15	<i>Cryptococcus hungaricus</i>	NCYC 3159	99.9	17.2	7.1	S	R
125	Jen-12	<i>Cryptococcus laurentii</i>	NCYC 3160	5.5	23.7	1.7	R	S
126	AB-24	<i>Cryptococcus laurentii</i>	NCYC 3161	7.4	15.5	1.5	R	S
127	Alf 03	<i>Cryptococcus laurentii</i>	UOFS Y-0514	7.6	20.1	1.6	R	S
128	AB-25	<i>Cryptococcus laurentii</i>	UOFS Y-1884	7.3	14.7	1.4	R	S
129	AB-26	<i>Cryptococcus laurentii</i>	UOFS Y-1885	10	15.2	1.5	R	S
130	AB-27	<i>Cryptococcus laurentii</i>	UOFS Y-1886	8.2	17.5	1.5	R	S
131	AB-32	<i>Cryptococcus laurentii</i>	UOFS Y-1887	5	15.9	1.4	R	S
132	AB-33	<i>Cryptococcus laurentii</i>	UOFS Y-1888	6.9	16	1.5	R	S

Sample No	Screen no	Yeast species	Culture Collection no.	Epoxide	Diol	E ^a	Abs.conf.	
				(%)	(%)		Epox.	Diol
133	Jen-9	<i>Cryptococcus laurentii</i> var. <i>laurentii</i>	UOFS Y-1349	1.3	28.4	1.8	R	S
134	Jen-16	<i>Cryptococcus luteolus</i>	NCYC 3162	0.1	27.4	1.8	R	S
135	BV-2	<i>Cryptococcus macerans</i>	NCYC 3213	9.2	70.2	6.2	R	S
136	AB-58	<i>Cryptococcus podzolicus</i>	NCYC 3164	4.7	88.2	16.7	S	R
137	AB-54	<i>Cryptococcus podzolicus</i>	UOFS Y-1900	6.8	2.8	1.1	S	R
138	AB-43	<i>Cryptococcus podzolicus</i>	UOFS Y-1902	6.5	0.8	1.1	S	R
139	AB-46	<i>Cryptococcus podzolicus</i>	UOFS Y-1907	10.1	94.1	36.4	S	R
140	AB-56	<i>Cryptococcus podzolicus</i>	UOFS Y-1913	11.1	92.1	27.2	S	R
141	AB-57	<i>Cryptococcus podzolicus</i>	UOFS Y-1914	12.8	96.9	73	S	R
142	113	<i>Debaryomyces hansenii</i>	NCYC 3167	4.6	27.4	1.8	R	S
143	520	<i>Pichia finlandica</i>	NCYC 3173	8.5	79.6	9.6	R	S
144	707	<i>Pichia guillermundii</i>	NCYC 3174	4.9	28.3	1.9	R	S
145	702	<i>Pichia guillermundii</i>	NCYC 3175	1.5	27.7	1.8	R	S
146	112	<i>Pichia guillermundii</i>	UOFS Y-0053	6.2	17.3	1.5	R	S
147	706	<i>Pichia guillermundii</i>	UOFS Y-0057	2.1	30	1.9	R	S
148	Alf 01	<i>Rhodospiridium toruloides</i>	NCYC 3181	0	36.9	2.2	S	R
149	Car-118	<i>Rhodospiridium toruloides</i>	NCYC 3182	5.5	29.3	1.9	S	R
150	POH-28	<i>Rhodospiridium toruloides</i>	NCYC 3215	9.1	15.2	1.5	S	R
151	POH-20	<i>Rhodospiridium toruloides</i>	NCYC 3216	5.2	13.5	1.4	S	R
152	POH-38	<i>Rhodospiridium toruloides</i>	NCYC 3219	14.6	11.4	1.4	S	R
153	46	<i>Rhodospiridium toruloides</i>	UOFS Y-0471	1.0	17.6	1.4	S	R
154	Alf 02	<i>Rhodospiridium toruloides</i>	UOFS Y-0518	1.5	37.9	2.3	S	R
155	Car-3	<i>Rhodospiridium toruloides</i>	UOFS Y-2222	3.5	25	1.7	S	R
156	Car-6	<i>Rhodospiridium toruloides</i>	UOFS Y-2223	1.7	26.5	1.8	S	R
157	Car-20	<i>Rhodospiridium toruloides</i>	UOFS Y-2226	3.7	24.4	1.7	S	R
158	Car-38	<i>Rhodospiridium toruloides</i>	UOFS Y-2228	2.4	36.7	2.2	S	R
159	Car-52	<i>Rhodospiridium toruloides</i>	UOFS Y-2230	5.3	27.8	1.9	S	R
160	Car-59	<i>Rhodospiridium toruloides</i>	UOFS Y-2231	0.4	25	1.7	S	R
161	Car-67	<i>Rhodospiridium toruloides</i>	UOFS Y-2236	2.7	31.3	2.0	S	R
162	Car-70	<i>Rhodospiridium toruloides</i>	UOFS Y-2237	4.8	21.2	1.6	S	R
163	Car-76	<i>Rhodospiridium toruloides</i>	UOFS Y-2238	5.9	22.1	1.7	S	R
164	Car-77	<i>Rhodospiridium toruloides</i>	UOFS Y-2239	4.5	22.8	1.7	S	R
165	Car-78	<i>Rhodospiridium toruloides</i>	UOFS Y-2240	3.8	29.9	1.9	S	R
166	Car-93	<i>Rhodospiridium toruloides</i>	UOFS Y-2242	3.0	22.7	1.6	S	R
167	Car-94	<i>Rhodospiridium toruloides</i>	UOFS Y-2243	4.7	31.8	2.0	S	R
168	Car-100	<i>Rhodospiridium toruloides</i>	UOFS Y-2245	4.8	24.3	1.7	S	R
169	Car-103	<i>Rhodospiridium toruloides</i>	UOFS Y-2246	2.1	23.5	1.6	S	R
170	Car-108	<i>Rhodospiridium toruloides</i>	UOFS Y-2247	3.8	24.9	1.7	S	R
171	Car-120	<i>Rhodospiridium toruloides</i>	UOFS Y-2249	3.4	27.0	1.8	S	R
172	Car-121	<i>Rhodospiridium toruloides</i>	UOFS Y-2250	5.0	29.6	1.9	S	R
173	Car-126	<i>Rhodospiridium toruloides</i>	UOFS Y-2251	5.4	18.9	1.5	S	R
174	Car-131	<i>Rhodospiridium toruloides</i>	UOFS Y-2252	3.3	26.2	1.8	S	R
175	Car-134	<i>Rhodospiridium toruloides</i>	UOFS Y-2253	3.6	23.7	1.7	S	R
176	Car-142	<i>Rhodospiridium toruloides</i>	UOFS Y-2255	5.5	22.4	1.7	S	R

Sample No	Screen no	Yeast species	Culture Collection no.	Epoxide	Diol	E ^a	Abs.conf.	
				ee	ee		Epox.	Diol
				(%)	(%)			
177	Car-200	<i>Rhodospiridium toruloides</i>	UOFS Y-2256	5.1	8.0	1.2	S	R
178	Car-204	<i>Rhodospiridium toruloides</i>	UOFS Y-2257	3.4	24.3	1.7	S	R
179	Car-205A	<i>Rhodospiridium toruloides</i>	UOFS Y-2258	1.9	25.5	1.7	S	R
180	Car-209	<i>Rhodospiridium toruloides</i>	UOFS Y-2260	6.4	22.0	1.7	S	R
181	Car-210	<i>Rhodospiridium toruloides</i>	UOFS Y-2261	4.6	27.6	1.8	S	R
182	POH-33	<i>Rhodospiridium toruloides</i>	NCYC 3218	11.2	10.1	1.4	S	R
183	EP-230	<i>Rhodotorula aurantiaca</i>	NCYC 3185	2.4	12.2	1.3	S	R
184	50	<i>Rhodotorula glutinis</i>	NCYC 3186	2.5	29.7	1.9	S	R
185	680	<i>Rhodotorula glutinis</i>	UOFS Y-0459	2.6	90.3	20.1	S	R
186	713	<i>Rhodotorula glutinis</i>	UOFS Y-0489	8.8	36.5	2.3	S	R
187	Alf 6	<i>Rhodotorula glutinis</i>	UOFS Y-0513	1.0	39.7	2.3	S	R
188	681	<i>Rhodotorula glutinis</i>	UOFS Y-0653	1.6	39.3	2.3	S	R
189	Car-22	<i>Rhodotorula glutinis</i>	UOFS Y-2227	2.7	14.9	1.4	S	R
190	Car-60	<i>Rhodotorula glutinis</i>	UOFS Y-2232	1.7	55.2	3.5	S	R
191	Car-61	<i>Rhodotorula glutinis</i>	UOFS Y-2233	6.6	28.2	1.9	S	R
192	Car-62	<i>Rhodotorula glutinis</i>	UOFS Y-2234	4.2	27.3	1.8	S	R
193	Car-66	<i>Rhodotorula glutinis</i>	UOFS Y-2235	4.0	27.7	1.8	S	R
194	Car-75	<i>Rhodotorula glutinis</i>	UOFS Y-2265	7.6	29.7	2.0	S	R
195	714	<i>Rhodotorula minuta</i>	NCYC 3187	99.2	14.7	5.1	R	S
196	686	<i>Rhodotorula minuta</i> var. <i>minuta</i>	NCYC 3188	100	51	25.8	R	S
197	712	<i>Rhodotorula minuta</i> var. <i>minuta</i>	UOFS Y-0835	100	3.3	4.2	R	S
198	158	<i>Rhodotorula sp. minuta</i> / <i>mucilaginosa</i>	NCYC 3194	16.4	2.4	1.2	R	S
199	690	<i>Rhodotorula sp. nearest minuta</i>	UOFS Y-0125	80.1	15.5	2.8	R	S
200	172	<i>Rhodotorula sp.</i>	NCYC 3192	4.1	15.1	1.4	S	R
201	24	<i>Rhodotorula sp.</i>	UOFS Y-2042	11.2	78.1	9.1	S	R
202	Jen-32	<i>Sporidiobolus salmonicolor</i>	NCYC 3195	5.4	76.1	7.8	S	R
203	Jen-29	<i>Sporobolomyces roseus</i>	NCYC 3197	3.3	17	1.5	R	S
204	Jen-28	<i>Sporobolomyces tsugae</i>	NCYC 3199	8.8	23.9	1.8	R	S
205	232	<i>Trichosporon cutaneum</i> var. <i>cutaneum</i>	NCYC 3202	32.0	80.3	12.5	S	R
206	20	<i>Trichosporon cutaneum</i> var. <i>cutaneum</i>	NCYC 3201	23.8	100	200	R	S
207	22	<i>Trichosporon jirovecii</i>	NCYC 3204	11.0	83.2	12.2	S	R
208	BV-4	<i>Trichosporon moniliiforme</i>	NCYC 3214	5.8	76.5	8.0	S	R
209	19	<i>Trichosporon ovoides</i>	NCYC 3207	20.8	38.8	2.8	R	S
210	231	<i>Trichosporon sp.</i>	NCYC 3210	7.1	73.7	7.1	S	R

^a E calculated from equation 3

All the yeast strains corresponding to samples 115-210 (Table 3) are kept and maintained at the University of the Orange Free State (UOFS), Department of Microbial, Biochemical and Food Biotechnology, Faculty of Natural and Agricultural Sciences, P.O. Box 339, Bloemfontein 9300, South Africa (Tel +27 51 401 2396, Fax + 27 51 444 3219) and are readily identified by the yeast species and culture collection number as indicated. Representative examples of strains belonging to the different species have been deposited under the Budapest Treaty at National Collection of Yeast Cultures (NCYC), Institute of Food Research Norwich Research Park Colney, Norwich NR4 7UA, U.K. (Tel: +44-(0)1603-255274 Fax: +44-(0)1603-458414 Email: ncyc@bbsrc.ac.uk) and are readily identified by the yeast species and culture collection accession numbers as indicated. The samples deposited with the NCYC are taken from the same deposit maintained by the South African Council for Scientific and Industrial Research (CSIR) since prior to the filing date of this application. The deposits will be maintained without restriction in the NCYC depository for a period of 30 years, or 5 years after the most recent request, or for the effective life of the patent, whichever is longer, and will be replaced if the deposit becomes non-viable during that period. Samples of the yeast strains not deposited at NCYC will be made available upon request on the same basis and conditions of the Budapest Treaty.

Three discrepancies were noted in the enantiopreferences for the aliphatic and aromatic epoxides:

1. *Bullera dendrophila* (NCYC 3152) was screened for both substrates and displayed variance in enantiopreference depending on the substituent: Se/Rd for 2-methyl-1,2-epoxyheptane and Re/Sd for 2-methyl-3-phenyl-1,2-epoxypropane.
2. *Cryptococcus curvatus*: Car 54 yielded Se/Rd for 2-methyl-1,2-epoxyheptane while Car 14 gave Re/Sd for 2-methyl-3-phenyl-1,2-epoxypropane.
3. *Trichopson cutaneum var cutaneum* (NCYC 3201) yielded Re/Sd for both epoxides, while NCYC 3202 yielded Re/Sd for 2-methyl-1,2-epoxyheptane but Se/Rd for 2-methyl-3-phenyl-1,2-epoxypropane.

These discrepancies can be due to the presence of more than one epoxide hydrolase having different activities towards aliphatic and aromatic substrates in these specific strains or to the incorrect classification of the strains. One skilled in the art will know how to test for such discrepancies and to proceed accordingly.

Example V. Testing of samples selected from Examples III and IV

Exemplary yeast strain samples selected from Table 2 and Table 3 were tested (in this Example as samples 211-223) for their ability to produce optically active epoxides and optically active vicinal diols from 2,2-disubstituted epoxides. For each sample, two graphs are provided. The first graph (graph A in each figure) shows the change in concentrations of the epoxide and diol enantiomers with time, while the second graph (graph B in each figure) shows the enantiomeric excess of the epoxide and diol at different conversions. The yield of the optically active epoxide or diol that can be obtained at the required enantiomeric purity can be seen from these graphs. The TDE that were used to illustrate the use of the different yeast strains to prepare optically active epoxides and vicinal diols from gem-2,2-disubstituted epoxides represented by the general formula (I) is shown in scheme I in (Fig. 1).

(a) Samples 211-219. Hydrolysis of ($\pm$)-2-methyl-1,2-epoxyheptane by selected yeasts to produce optically active (S)-2-methyl-1,2-epoxyheptane (1a) and/or (R)-2-methyl-1,2-heptanediol (1b) (Figs. 2A – 10B).

Hydrolysis of ($\pm$)-2-methyl-1,2-epoxyheptane by yeast strains selected from Table 2 was performed as described in Example I to produce (S)-2-methyl-1,2-epoxyheptane and/or (R)-2-methyl-1,2-heptanediol.

(b) Sample 220. Hydrolysis of ($\pm$)-2-methyl-1,2-epoxyheptane by selected yeasts to produce optically active (R)-2-methyl-1,2-epoxyheptane and/or (S)-2-methyl-1,2-heptanediol (Figs. 11A and B).

Hydrolysis of ($\pm$)-2-methyl-1,2-epoxyheptane by yeast strains selected from Table 2 was performed as described in Example I to produce (R)-2-methyl-1,2-epoxyheptane and/or (S)-2-methyl-1,2-heptanediol.

(c) Sample 221. Hydrolysis of ($\pm$)-2-methyl-3-phenyl-1,2-epoxypropane by selected yeasts to produce optically active (S)-2-methyl-3-phenyl-1,2-epoxypropane and/or (R)-2-methyl-3-phenyl-1,2-propanediol (Figs. 12A and 12B).

Hydrolysis of ($\pm$)-2-methyl-3-phenyl-1,2-epoxypropane by a yeast strain selected from Table 3 was performed as described in Example I to produce (S)-2-methyl-3-phenyl-1,2-epoxypropane and/or (R)-2-methyl-3-phenyl-1,2-propanediol.

(d) Samples 222 and 223. Hydrolysis of ($\pm$)-2-methyl-3-phenyl-1,2-epoxypropane by selected yeasts to produce optically active (R)-2-methyl-3-phenyl-1,2-epoxypropane

and/or (S)- 2-methyl-3-phenyl-1,2-propanediol (Figs. 13A to 14B)

Hydrolysis of ($\pm$)-2-methyl-3-phenyl-1,2-epoxypropane by yeasts selected from Table 3 was performed as described in Example I to produce (R)-2-methyl-3-phenyl-1,2-epoxypropane and/or (S)-2-methyl-3-phenyl-1,2-propanediol.

5

Example VI. Hydrolysis of ($\pm$)-2-methyl-3-phenyl-1,2-epoxypropane by a yeast cultivated in a 10 L fermenter to produce optically active (S)-2-methyl-3-phenyl-1,2-epoxypropane and/or (R)-2-methyl-3-phenyl-1,2-propanediol

10 Figs. 15A to 15B show hydrolysis of ($\pm$)-2-methyl-3-phenyl-1,2-epoxypropane by a yeast (Sample 224) cultivated in a 10 L fermenter to produce optically active (S)- 2-methyl-3-phenyl-1,2-epoxypropane and/or (R)-2-methyl-3-phenyl-1,2-propanediol.

Example VII. Hydrolysis of ($\pm$)-2-methyl-3-phenyl-1,2-epoxypropane by recombinant yeast expression hosts transformed with the epoxide hydrolase genes from different wild type yeast strains

15

Figs. 16A to 18B show hydrolysis of ($\pm$)-2-methyl-3-phenyl-1,2-epoxypropane by recombinant yeasts (as samples 225-227) expressing epoxide hydrolases from selected wild type yeast strains to produce optically active (S)- 2-methyl-3-phenyl-1,2-epoxypropane and/or (R)-2-methyl-3-phenyl-1,2-propanediol.

20

(a) **Sample 225.** Hydrolysis of ($\pm$)-2-methyl-3-phenyl-1,2-epoxypropane by host *Yarrowia lipolytica* cells transformed with the epoxide hydrolase coding sequence from *Rhodotorula araucariae* (NCYC 3183) (Fig. 16). The host strain is Po1h, the vector used was the pINA 1297 zeta-based auto-cloning multicopy vector from which a "yeast cassette" can be purified and integrated non-homologously into the genome of Po1h. The expression of the epoxide hydrolase gene is driven by the hp4d promoter. The XPR2 secretion signal was replaced by the LIP2 secretion signal in the vector. (See Madzak *et al.*, Journal of Biotechnology 109, 2004). Reaction conditions: 50 % (w/v) cell suspension, 50 mM ($\pm$)-2-methyl-3-phenyl-1,2-epoxypropane.

25

30

(b) **Sample 226.** Hydrolysis of ($\pm$)-2-methyl-3-phenyl-1,2-epoxypropane by host *Yarrowia lipolytica* cells transformed with the epoxide hydrolase coding sequence from *Rhodospiridium paludigenum* (NCYC 3179) (Fig. 17). The host strain is Po1h. The expression of the epoxide hydrolase gene is driven by the constitutive TEF promoter. (See Madzak *et al.*, Journal of Biotechnology 109, 2004). Reaction conditions: 50% (w/v) cell

35

suspension, 100 mM ($\pm$)-2-methyl-3-phenyl-1,2-epoxypropane.

(c) **Sample 227.** Hydrolysis of ($\pm$)-2-methyl-3-phenyl-1,2-epoxypropane by the host *Yarrowia lipolytica* transformed with the gene from *Rhodospiridium paludigenum* UOFS Y-0482/NCYC 3179 (Fig. 18). The host strain is Po1h. The expression of the epoxide hydrolase gene is driven by the hp4d promoter. (See Madzak *et al.*, Journal of Biotechnology 109, 2004). Reaction conditions: 10 % (w/v) cell suspension, 100 mM ($\pm$)-2-methyl-3-phenyl-1,2-epoxypropane.

Example VIII. Hydrolysis of ($\pm$)-2-methyl-3-phenyl-1,2-epoxypropane by a crude enzyme preparation obtained from the host *Yarrowia lipolytica* expressing the epoxide hydrolase derived from *Rhodotorula araucariae* NCYC 3183 (YL 25 TsA)

Figs. 19A and 19B show hydrolysis of ($\pm$)-2-methyl-3-phenyl-1,2-epoxypropane by the epoxide hydrolase derived from *Rhodotorula araucariae* NCYC 3183 (YL 25 TsA) expressed in *Yarrowia lipolytica*. Fig 19A shows hydrolysis by whole cells and Fig. 19B shows hydrolysis by a crude enzyme preparation obtained from the cells

Example IX. Amino acid sequences of enantioselective epoxide hydrolase polypeptide for the hydrolysis of ($\pm$)-2,2-disubstituted epoxides to produce optically active epoxides and/or diols.

The sequences with SEQ ID NOs: 1-5 (Figs. 22-26) are examples of amino acid sequences of enantioselective epoxide hydrolases for the hydrolysis of ($\pm$)-2,2-disubstituted epoxides to produce optically active (S)-epoxides and/or (R)-diols. The cDNAs encoding the polypeptides were obtained as described in Example II from the indicated yeast strains.

The sequences with SEQ ID NOs: 6 and 7 (Figs. 27 and 28) are examples of amino acid sequences of enantioselective epoxide hydrolases for the hydrolysis of ($\pm$)-2,2-disubstituted epoxides to produce optically active (R)-epoxides and/or (S)-diols. The cDNAs encoding the polypeptides were obtained as described in Example II from the indicated yeast strains.

Example X. Nucleotide sequences of enantioselective epoxide hydrolase genes for the hydrolysis of ($\pm$)-2,2-disubstituted epoxides to produce optically active epoxides and/or diols.

The sequences with SEQ ID NOs: 8-12 (Figs. 29-33) are examples of cDNA sequences

encoding enantioselective epoxide hydrolase genes for the hydrolysis of ($\pm$)-2,2-disubstituted epoxides to produce optically active (S)-epoxides and/or (R)- diols. The cDNAs encoding the polypeptides were obtained as described in Example II from the indicated yeast strains.

5

The sequences with SEQ ID NOs:13 and 14 (Fig. 34 and 35) are examples of cDNA sequences encoding enantioselective epoxide hydrolase genes for the hydrolysis of ($\pm$)-2,2-disubstituted epoxides to produce optically active (R)-epoxides and/or (S)- diols. The cDNAs encoding the polypeptides were obtained as described in Example II from the indicated yeast strains.

10

Example XI. Homology at the amino acid level of enantioselective epoxide hydrolases for the hydrolysis of ($\pm$)-2,2-disubstituted epoxides to produce optically active epoxides and/or diols.

15

Fig. 36 shows the percent homology at the amino acid level of enantioselective epoxide hydrolases described in the Example IX. Alignments were done using DNAMAN Version 5.2.9 (Lynnon Biosoft) software using the multiple sequence alignment mode (Fast alignment/Quick alignment settings).

20

Example XII. Homology at nucleotide level of enantioselective epoxide hydrolase cDNA for the hydrolysis of ($\pm$)-2,2-disubstituted epoxides to produce optically active epoxides and/or diols.

25

Fig. 37 shows the percent homology at the nucleotide level of cDNAs encoding the enantioselective epoxide hydrolases described in Example X. Alignments were done in DNAMAN Version 5.2.9 (Lynnon Biosoft) software using the multiple sequence alignment mode (Fast alignment/Quick alignment settings).

30

References cited

Madzak, C., Gaillardin, C., Beckerich, J-M. (2004). Heterologous protein expression and secretion in the non-conventional yeast *Yarrowia lipolytica*: a review. *Journal of Biotechnology* 109: 63-81.

35

Mischitz, M.; Kroutil, W.; Wandel, U.; Faber, K. *Tetrahedron Asymmetry* 1995, 6, 1261-

1272.

Nicaud J-M, Madzak C, Van den Broek P, Gysler C, Duboc P, Niederberger P, Gaillardin C. (2002) Protein expression and secretion in the yeast *Yarrowia lipolytica*. FEMS Yeast Research 2, 371-279.

- 5 **Orru, R.V.A., Mayer, S., Kroutil, W. and Faber, K.** (1998) Chemoenzymatic deracemization of ($\pm$)-2,2-disubstituted oxiranes. *Tetrahedron* 54: 859-874

Pedragosa-Moreau, S., Archelas, A. and Furstoss, R. (1996) Microbiological Transformations 32. Use of epoxide hydrolase mediated biohydrolysis as a way to enantiopure epoxides and vicinal diols - Application to substituted styrene oxide derivatives. *Tetrahedron* 52: 4593-4606.

- 10 **Steinreiber, A., Osprian, I., Mayer, S.F., Orru, R.V. and Faber, K.** (2000) Enantioselective hydrolysis of functionalized 2,2-disubstituted oxiranes with bacterial epoxide hydrolases. *Eur. J. Org. Chem.* 22: 3703-3711.

- Xuan J-W, Fournier P, Gaillardin C.** (1988) Cloning of the *LYS5* gene encoding saccharopine dehydrogenase from the yeast *Yarrowia lipolytica* by target integration. *Current Genetics* 14, 15-21.

A number of embodiments of the invention have been described. Nevertheless; it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.

WHAT IS CLAIMED IS:

1. A process for obtaining an optically active epoxide or an optically active vicinal diol, which process includes the steps of:
 - 5 providing an enantiomeric mixture of a 2,2-disubstituted epoxide;
 - creating a reaction mixture by adding to the enantiomeric mixture a polypeptide, or a functional fragment thereof, having enantioselective 2,2-disubstituted epoxide hydrolase activity, the polypeptide being a polypeptide encoded by a gene of a yeast cell;
 - incubating the reaction mixture; and
 - 10 recovering from the reaction mixture: (a) an enantiopure, or a substantially enantiopure, 2,2-disubstituted vicinal diol; (b) an enantiopure, or a substantially enantiopure, 2,2-disubstituted epoxide; or (c) an enantiopure, or a substantially enantiopure, 2,2-disubstituted vicinal diol and an enantiopure, or a substantially enantiopure, 2,2-disubstituted epoxide.
- 15 2. A process for obtaining an optically active epoxide or an optically active vicinal diol, which process includes the steps of:
 - providing an enantiomeric mixture of a 2,2-disubstituted epoxide;
 - creating a reaction mixture by adding to the enantiomeric mixture a cell comprising a
20 nucleic acid encoding, and capable of expressing, a polypeptide having enantioselective 2,2-disubstituted epoxide hydrolase activity, the polypeptide being a polypeptide encoded by a gene of a yeast cell;
 - incubating the reaction mixture; and
 - recovering from the reaction mixture: (a) an enantiopure, or a substantially enantiopure, 2,2-disubstituted vicinal diol; (b) an enantiopure, or a substantially enantiopure, 2,2-disubstituted epoxide; or (c) an enantiopure, or a substantially enantiopure, 2,2-disubstituted vicinal diol and an enantiopure, or a substantially enantiopure, 2,2-disubstituted epoxide.
- 25 3. The process of claims 1 or 2, wherein the cell is a yeast cell.
4. The process of claims 1 to 3, wherein the polypeptide is encoded by an endogenous gene of the cell.
- 35 5. The process of claims 2 or 3, wherein the cell is a recombinant cell and the

polypeptide is encoded by a nucleic acid sequence with which the cell is transformed.

6. The process of claim 5, wherein the nucleic acid sequence is a heterologous nucleic acid sequence.

5

7. The process of claim 5, wherein the nucleic acid sequence is a homologous nucleic acid sequence.

10

8. The process of any of claims 1 to 7, wherein the polypeptide is a full-length yeast epoxide hydrolase.

9. The process of any of claims 1 to 7, wherein the polypeptide is a functional fragment of yeast epoxide hydrolase.

15

10. The process of any one of claims 1 to 9, wherein the process is carried out at a pH from 5 to 10.



20

11. The process of any one of claims 1 to 10, wherein the process is carried out at a temperature of 0°C to 70 °C.

12. The process of any one of claims 1 to 11, wherein the concentration of the 2,2-disubstituted epoxide in the reaction matrix is at least equal to the soluble concentration of the 2,2-disubstituted epoxide in water.

25

13. The process of any one of claims 1 to 12, wherein the 2,2-disubstituted epoxide of the enantiomeric mixture is a compound of the general formula (I) and the vicinal diol produced by the process is a compound of the general formula (II),



30

wherein:

R_1 and R_2 are, independently of each other, selected from the group consisting of a variably substituted straight-chain or branched alkyl group, a variably substituted straight-chain or branched alkenyl group, a variably substituted straight-chain or branched alkynyl group, a variably substituted cycloalkyl group as well as cycloalkenyl groups, a variably substituted aryl group, a variably substituted aryl alkyl group, a variably substituted heterocyclic group, a variably substituted straight-chain or branched alkoxy group, a variably substituted straight-chain or branched alkenyloxy group, a variably substituted aryloxy group, a variably substituted aryl alkyloxy group, a variably substituted alkylthio group, a variably substituted alkoxycarbonyl group, a variably substituted straight chain or branched alkylamino or alkenyl amino group, a variably substituted arylamino or arylalkylamino group, a variably substituted carbamoyl group, a variably substituted acyl group, and a functional group; or wherein R_1 and R_2 , together as a whole unit are a carbocycle with 5 to 7 atoms or a heterocycle with 5 to 7 carbon atoms.

14. The process of any of claims 1 to 13, wherein the enantiomeric mixture is a racemic mixture or a mixture of any ratio of amounts of the enantiomers.

15. The process of any of claims 1 to 14, which process includes adding to the reaction water and at least one water-immiscible solvent.

16. The process of claim 15, wherein the water-immiscible solvent is selected from the group consisting of toluene, 1,1,2-trichlorotrifluoroethane, methyl *tert*-butyl ether, methyl isobutyl ketone, dibutyl-*o*-phthalate, aliphatic alcohols containing 6 to 9 carbon atoms, and aliphatic hydrocarbons containing 6 to 16 carbon atoms.

17. The process of any of claims 1 to 14, which process includes adding to the reaction water and at least one water-miscible organic solvent.

18. The process of claim 17, wherein the water-miscible solvent is selected from the group consisting of acetone, methanol, ethanol, propanol, isopropanol, acetonitrile, dimethylsulfoxide, *N,N*-dimethylformamide, and *N*-methylpyrrolidine.

19. The process of any one of claims 1 to 18, which process includes adding to the reaction mixture at least one reagent selected from the group consisting of one or more surfactants, one or more cyclodextrins, and one or more phase-transfer catalysts.

20. The process of any one of claims 1 to 19, which process includes stopping the reaction when one enantiomer of the epoxide and/or vicinal diol is in excess compared to the other enantiomer of the epoxide and/or vicinal diol.

5 21. The process of any one of claims 1 to 20, which process includes recovering continuously during the reaction the optically active epoxide and/or the optically active vicinal diol produced by the reaction directly from the reaction mixture.

10 22. A process of any of claims 1 to 21, wherein the yeast cell is of a yeast genus selected from the group consisting of *Arxula*, *Brettanomyces*, *Bullera*, *Bulleromyces*, *Candida*, *Cryptococcus*, *Debaryomyces*, *Dekkera*, *Exophiala*, *Geotrichum*, *Hormonema*, *Issatchenkia*, *Kluyveromyces*, *Lipomyces*, *Mastigomyces*, *Myxozyma*, *Pichia*, *Rhodospiridium*, *Rhodotorula*, *Sporidiobolus*, *Sporobolomyces*, *Trichosporon*, *Wingea*, or *Yarrowia*.

15 23. The process of any of claims 1 to 21, wherein the yeast cell is of a yeast species selected from the group consisting of *Arxula adenivorans*, *Arxula terrestris*, *Brettanomyces bruxellensis*, *Brettanomyces naardenensis*, *Brettanomyces anomalus*, *Brettanomyces species* (e.g. NCYC 3151), *Bullera dendrophila*, *Bulleromyces albus*,
20 *Candida albicans*, *Candida fabianii*, *Candida glabrata*, *Candida haemulonii*, *Candida intermedia*, *Candida magnoliae*, *Candida parapsilosis*, *Candida rugosa*, *Candida tenuis*, *Candida tropicalis*, *Candida famata*, *Candida kruisei*, *Candida sp. (new) rel to C. sorbophila*, *Cryptococcus albidus*, *Cryptococcus amyloletus*, *Cryptococcus bhutanensis*, *Cryptococcus curvatus*, *Cryptococcus gastricus*, *Cryptococcus humicola*, *Cryptococcus*
25 *hungaricus*, *Cryptococcus laurentii*, *Cryptococcus luteolus*, *Cryptococcus macerans*, *Cryptococcus podzolicus*, *Cryptococcus terreus*, *Cryptococcus macerans*, *Debaryomyces hansenii*, *Dekkera anomala*, *Exophiala dermatitidis*, *Geotrichum species* (e.g. UOFS Y-0111), *Hormonema species* (e.g. NCYC 3171), *Issatchenkia occidentalis*, *Kluyveromyces marxianus*, *Lipomyces species* (e.g. UOFS Y-2159), *Lipomyces tetrasporus*, *Mastigomyces philipporii*, *Myxozyma melibiosi*, *Pichia anomala*, *Pichia finlandica*, *Pichia guillermondii*,
30 *Pichia haplophila*, *Rhodospiridium lusitaniae*, *Rhodospiridium paludigenum*, *Rhodospiridium sphaerocarpum*, *Rhodospiridium toruloides*, *Rhodospiridium paludigenum*, *Rhodotorula araucariae*, *Rhodotorula glutinis*, *Rhodotorula minuta*, *Rhodotorula minuta var. minuta*, *Rhodotorula mucilaginoso*, *Rhodotorula philyla*,
35 *Rhodotorula rubra*, *Rhodotorula species* (e.g. UOFS Y-2042), *Rhodotorula species* (e.g.

UOFS Y-0448), *Rhodotorula species* (e.g. NCYC 3193), *Rhodotorula species* (e.g. UOFS Y-0139), *Rhodotorula species* (e.g. UOFS Y-0560), *Rhodotorula aurantiaca*, *Rhodotorula species* (e.g. NCYC 3224), *Rhodotorula sp. "mucilaginoso"*, *Sporidiobolus salmonicolor*, *Sporobolomyces holsaticus*, *Sporobolomyces roseus*, *Sporobolomyces tsugae*,
5 *Trichosporon beigelii*, *Trichosporon cutaneum* var. *cutaneum*, *Trichosporon delbrueckii*,
Trichosporon jirovecii, *Trichosporon mucoides*, *Trichosporon ovoides*, *Trichosporon pullulans*, *Trichosporon species* (e.g. UOFS Y-0861), *Trichosporon species* (e.g. UOFS Y-1615), *Trichosporon species* (e.g. UOFS Y-0451), *Trichosporon species* (e.g. NCYC 3212),
10 *Trichosporon species* (e.g. UOFS Y-0449), *Trichosporon species* (e.g. NCYC 3211),
Trichosporon species (e.g. UOFS Y-2113), *Trichosporon species* (e.g. NCYC 3210),
Trichosporon moniliiforme, *Trichosporon montevidense*, *Wingea robertsiae*, or *Yarrowia lipolytica*.

24. A method for producing a polypeptide, which process includes the steps of:
15 providing a cell comprising a nucleic acid encoding and capable of expressing a polypeptide that has enantioselective 2,2-disubstituted epoxide hydrolase activity;
culturing the cell; and
recovering the polypeptide from the culture.

20 25. The method of claim 24, wherein the cell is a yeast cell.

26. The method of claims 24 or 25, wherein the polypeptide is a full-length yeast epoxide hydrolase.

25 27. The method of any of claims 24 or 25, wherein the polypeptide is a functional fragment of a yeast epoxide hydrolase.

28. The method of any of claims 24-27, wherein the polypeptide is encoded by an endogenous gene of the cell.

30 29. The method of claims 22-27, wherein the cell is a recombinant cell and the polypeptide is encoded by a nucleic acid sequence with which the cell is transformed.

35 30. The method of claim 29, wherein the nucleic acid sequence is a heterologous nucleic acid sequence.

31. The method of claim 30, wherein the nucleic acid sequence is a homologous nucleic acid sequence.

5 32. A crude or pure enzyme preparation which includes an isolated polypeptide having enantioselective 2,2-disubstituted epoxide hydrolase activity.

10 33. A substantially pure culture of cells, a substantial number of which comprise a nucleic acid encoding, and are capable of expressing, a polypeptide having enantioselective 2,2-disubstituted epoxide hydrolase activity.

34. An isolated cell, the cell comprising a nucleic acid encoding a polypeptide having enantioselective 2,2-disubstituted epoxide hydrolase activity, the cell being capable of expressing the polypeptide.

15 35. An isolated DNA comprising:

(a) a nucleic acid sequence that encodes a polypeptide that has enantioselective 2,2-disubstituted epoxide hydrolase activity and that hybridizes under highly stringent conditions to the complement of a sequence selected from the group consisting of SEQ ID NOs: 8, 9, 10, 11, 12, 13, and 14; or

20 (b) the complement of the nucleic acid sequence.

36. The DNA of claim 35, wherein the nucleic acid sequence encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, and 7.

25 37. The DNA of claim 35, wherein the nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 8, 9, 10, 11, 12, 13, and 14.

38. An isolated DNA comprising:

30 (a) a nucleic acid sequence that is at least 55% identical to a sequence selected from the group consisting of SEQ ID NOs: 8, 9, 10, 11, 12, 13, and 14; or

(b) the complement of the nucleic acid sequence,

wherein the nucleic acid sequence encodes a polypeptide that has enantioselective 2,2-disubstituted epoxide hydrolase activity.

35

39. An isolated DNA comprising:

(a) a nucleic acid sequence that encodes a polypeptide consisting of an amino acid sequence that is at least 55% identical to a sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6 and 7; or

5 (b) the complement of the nucleic acid sequence,
wherein the polypeptide has enantioselective 2,2-disubstituted epoxide hydrolase activity.

40. An isolated polypeptide encoded by the DNA of claims 33-37.

10 41. An isolated polypeptide comprising an amino acid sequence that is at least 55% identical to SEQ ID NOs: 1, 2, 3, 4, 5, 6, or 7, the polypeptide having enantioselective 2,2-disubstituted epoxide hydrolase activity.

42. The polypeptide of claim 41, comprising:

15 (a) a sequence selected from the group consisting of SEQ ID NOs; 1, 2, 3, 4, 5, 6 and 7, or a functional fragment of the sequence; or

(b) the sequence of (a), but with no more than five conservative substitutions,
wherein the polypeptide has enantioselective 2,2-disubstituted epoxide hydrolase activity.

20 43. An isolated antibody that binds to the polypeptide of any of claims 40-42.

44. The antibody of claim 43, wherein the antibody is polyclonal antibody.

45. The antibody of claim 43, wherein the antibody is a monoclonal antibody.